

CURRICULUM VITAE
ROMAN PEREZ-SOLER, M.D.

Present Title and Affiliation: Professor of Medicine
Chairman, Department of Oncology
Montefiore Medical Center
Director, Division of Medical Oncology
Albert Einstein College of Medicine
Associate Director for Clinical Research
Albert Einstein Comprehensive Cancer Center
Bronx, New York

Birth Date and Place: October 17, 1953; Barcelona, Spain

Citizenship: United States (Fluent in Spanish and French)

Social Security Number: 451-59-5634

Home Address: 301 West 57th Street, #45B **Telephone:** (212) 664- 0289
New York, NY 10019

87 Old Field Road. **Telephone:** (631) 941-1306
Setauket, NY 11733 **Fax :** (631) 941-1047

Office Address: 111 East 210th Street **Telephone:** (718) 920-7100
Bronx, New York 10467 **Fax:** (718) 798-7474

Marital Status: Married, two children

Licensures - Active: July 1977 ECFMG 292-303-5
September 1978 VQE
June 1984 FLEX
July 1985 Texas Medical License G-8336
August 1998 New York License #211726-1

Education: 1971-1977: Medicine, Universidad Autonoma
Barcelona, Spain

E-mail Address: rperezso@montefiore.org

Postgraduate Training:

April 1978 - March 1979
Internship
Barcelona, Spain

April 1979 - May 1982
Residency - Internal Medicine
Barcelona, Spain

July 1982 - June 1984
Fellowship in Medical Oncology
The University of Texas System Cancer Center
M. D. Anderson Hospital and Tumor Institute
Houston, TX 77030

July 1984 - June 1985
Fellowship in Medical Oncology
Laboratory of Immunobiology and Drug Carriers
(Dr. G. Lopez-Berestein)
The University of Texas System Cancer Center
M. D. Anderson Hospital and Tumor Institute
Houston, TX 77030

Specialty Boards:

Diplomate in Internal Medicine by the American Board of Internal Medicine, 1987
Diplomate in Medical Oncology by the American Board of Internal Medicine, 1989

Academic and Professional Appointments:

July 1985 - September 1990
Assistant Professor of Medicine, Assistant Internist
Department of Clinical Immunology and Biological Therapy
The University of Texas M. D. Anderson Cancer Center
Houston, TX

December 1988 - August 1996
Faculty Member
Graduate School of Biomedical Sciences
The University of Texas Health Science Center at Houston
Houston, TX

April 1989 - August 1997
Adjunct Associate Professor of Pharmaceutics
University of Houston School of Pharmacy
Houston, TX

October 1990 - August 1991
Assistant Professor of Medicine, Assistant Internist

Department of Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

September 1991 - December 1992
Associate Professor of Medicine, Associate Internist
Department of Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

January 1993 - August 1997
Associate Professor of Medicine, Associate Internist
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

July 1994 – July 1998
Chief, Section of Experimental Therapy
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, TX

January 1996 – July 1998
Deputy Chairman
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, TX

September 1997 – July 1998
Professor of Medicine, Internist
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, TX

August 1998 – July 2001
Professor of Medicine
Associate Director of Clinical and Transnational Research
Kaplan Comprehensive Cancer Center
New York University Medical Center
New York, NY

July 2001 - Present
Professor of Medicine
Chairman, Department of Oncology
Montefiore Medical Center
Director, Division of Medical Oncology
Albert Einstein College of Medicine
Bronx, New York

Administrative Responsibilities:

M. D. Anderson Cancer Center :

1987 - 1991	Member, Infection Control Subcommittee of the Medical Staff
1988 - 1989	Member, Research Committee
1992 - 1995	Member, Intellectual Property Committee
1993 - 1994	Member, Medical Practice Subcommittee of the Medical Staff
1993 - 1998	Member, Faculty Senate
1993 - 1995	Member, Academic Planning Committee of Faculty Senate
1993 - 1998	Member, Ethics Committee of Faculty Senate
1993 - 1994	Member, Institutional Research Support Committee
1994 - 1997	Member, Fringe Benefits and Compensation Committee, Physician's Referral Service
1994 - 1996	Chairman, Ad-Hoc Committee on Faculty Travel Policy of Faculty Senate
1994 - 1995	Vice-Chairman, Institutional Research Support Committee
1994 - 1995	Member, Criteria for Promotion and Compensation Committee, Division of Medicine
1995 - 1996	Chairman, Institutional Research Support Committee
1995 - 1997	Member, Clinical Research Committee
1995 - 1996	Member, Medical Record Subcommittee of the Medical Staff
1995 - 1996	Member, Research Direction Working Group
1995 - 1998	Member, Physician's Referral Service Scientific Review Committee
1995 - 1998	Member, Executive Committee of Faculty Senate
1995 - 1997	Chairman, Academic Planning Committee of Faculty Senate
1996 - 1998	Member, Division of Medicine Promotions Committee
1996 - 1998	Member, Physician's Referral Service Executive Council
1997 - 1998	Chairman-Elect, Faculty Senate
1997 - 1998	Director, Lung Cancer Research Program
1998	Member, Board of Directors, M. D. Anderson Physicians Network
1998	Chairman, Ovarian Cancer Program Grant Review Committee

**New York University
(Kaplan Cancer Center)**

1998-2000	Associate Director for Clinical Oncology and Translational Research
1998	Member, Clinical Management Executive Committee
1998	Member, Executive Management Committee
1998	Member, Executive Advisory Committee, NYU General Clinical Research Center
1998	Leader, Upper Aerodigestive and Lung Cancer Program
1999	Member, International Patient Program, New York University Medical Center
2000	Associate Director for Clinical and Translational Research
2001	Chairman, Membership Committee

Albert Einstein College of Medicine/Montefiore Medical Center

2001	Associate Director for Clinical Research, Cancer Center
2001	Member, Steering Committee, Cancer Center
2001	Member, Executive Committee, Cancer Center
2001	Patent Committee, College of Medicine
2001	Executive Committee of the Medical Staff, Montefiore Medical Center

National and International:

- 1998 – 1999 American Association for Cancer Research Annual Meeting, Program Committee
Co-Chairperson, Drug Discovery, Design, Screening and Delivery Systems Section
- 1999 – Member, Membership Committee
American Association for Cancer Research
– 2000 American Association for Cancer Research Annual Meeting, Program Committee
Member, Organ Site Specific Preclinical Studies

Memberships in Peer Review Committees:

NIH, Special Review Committee, PO1, Alan Morgan, P.I.
University of Toledo, OH
June 5-7, 1989
June 7-9, 1992

NIH, Biological Sciences Special Study Section Z
July 12-14, 1990
July 12-14, 1994
November 1-2, 1994
March 5 - 6, 1995
July 9 - 10, 1995
November 5 - 6, 1995

NIH, SPORE in Breast Cancer Review Committee, Washington, DC
February 28 - March 3, 1995

NIH, Experimental Therapeutics - 2 Study Section
October 30 - November 1, 1996
February 26 - 28, 1997
June 25-27, 1997
October 29-31, 1997
March 1-4, 1998
July 1-3, 1998
October 19-21, 1998
February 24-26, 1999
June 30- July 2, 1999
Chartered Member 1999-2002

NIH, Oncological Sciences Special Study Section ARG2
March 24 - 25, 1997
July 14-15, 1997
March 22-23, 1998
March 6, 2000
July 17-18, 2000

National Cancer Institute of Canada, Toronto, Canada
Experimental Therapeutics and Carcinogenesis Panel G
January 26-28, 1998

National Cancer Institute
Subcommittee H
September 1, 2001-June 30, 2004

Memberships in Editorial Boards

Associate Editor, Clinical Cancer Research
Associate Editor, Journal of Clinical Oncology, Spanish Edition
Investigational New Drugs
PDQ Adult treatment

Peer Review of Journal Articles and Grants:

American Journal of the Chemical Society
Biochemical Pharmacology
British Journal of Cancer
Arnold Yeldham and Mary Raine Medical Research Foundation (Australia)
Cancer
Cancer Research
Cancer Chemotherapy and Pharmacology
Clinical Cancer Research
Dutch Cancer Society
International Journal of Cancer
Journal of Clinical Investigation
Journal of Clinical Oncology
Journal of Leukocyte Biology
Journal of Medicinal Chemistry
Journal of the National Cancer Institute
Journal of Pharmaceutical Sciences
Louisiana Cancer and Lung Trust Fund Board
Medical Research Council of Canada
North Carolina Biotechnology Center
Oncology Research
Pharmaceutical Research
Urology

Consultantships:

1986 - 1990 The Liposome Company, Inc. Princeton, NJ
1988 - Present Aronex Pharmaceuticals, Inc. The Woodlands, TX
1989 - 1992 LNETI, Lisbon, Portugal
1994 - 1998 NIH 1RO1 CA 63653: Lipophilic camptothecins for cancer treatment.
 P.I.: Thomas Burke, Ph.D.
1995 - 2000 Member, SmithKline Beecham Oncology Advisory Board, Philadelphia, PA
1997 - 1998 Member, Agouron Lung Cancer Advisory Board, San Diego, CA
1998 - Present Member, Pfizer Lung/Head and Neck Cancer Advisory Board, New York, NY

04/22/02

1999 - 2000 Kelman Research Foundation, New York, NY
1999 - 2000 Almirall- Prodesfarma, Barcelona, Spain
2000 - Present Eye and Ear Foundation, University of Pittsburgh, Pittsburgh, PA
2000 - Present Direct Therapeutics Inc., San Ramon, CA
2000 - Present Transave, Inc., Princeton, NJ
Co-Chair of Scientific Advisory Board
Member, Board of Directors
2000 - Present Fundacion M. Botin (Gene Therapy), Instituto de Espana, Madrid, Spain
2000- Present OSI Pharmaceuticals, Inc., Uniondale, NY
2000- Present Laboratorios Esteve, Barcelona, Spain

Honors and Awards:

Honors Mention -

1972 - Biochemistry; 1973 - Anatomy, Physiology; 1974 - General Pathology, Anatomical Pathology, Microbiology, Pharmacology; 1975 - Internal Medicine, Obstetrics, Ophthalmology, Psychiatry, Dermatology; 1976 - Internal Medicine, Gynecology, Surgery; 1977 - Emergency Medicine

1977 Medical Degree with Outstanding Award Universidad Autonoma, Barcelona, Spain

7/81 - 6/82 Research Scholarship
Ministry of Education and Research, Madrid, Spain
Field: Platelet function in alcoholism

9/83 - 6/85 Fulbright Research Scholarship
Field: Monocyte function in Hodgkin's Disease

6/85 Certificate of Merit for Outstanding
Accomplishment of an Independent Research Project,
Annual Clinical Training Research
Project Competition for Fellows, Residents and Project Investigators
M. D. Anderson Hospital and Tumor Institute, Houston, TX

6/85 Achievement in Research Award Fellowship Program, Division of Medicine
M. D. Anderson Hospital and Tumor Institute, Houston, TX

9/89 Faculty Excellence Award, M. D. Anderson Cancer Center, Houston, TX

6/90 Doctorate in Medicine "Cum Laude"
Universidad Autonoma, Barcelona, Spain

10/93 Finalist, Julie and Ben Rogers Award for Excellence

Society Memberships:

American Society of Clinical Oncology
American Association for Cancer Research
American Association for the Advancement for Science

Sponsorship of Postdoctoral Fellows:

1985 - 1986	Julio Lautersztain, M.D.
1990 - 1991	Jim Partyka, Pharm. D.
1990 - 1992	Steve Sugarman, M.D.
1991 - 1994	Yiyu Zou, Ph.D.
1991 - 1994	Insook Han, Ph.D.
1997 - 1998	Don McLean, Ph.D.
1999 - present	Luis Lopez-Barcons, Ph.D.

Sponsorship of Visiting Fellows:

1987 - 1988	Francisca Lopes, Pharm.D. LNETI, Lisbon, Portugal
1988 - 1990	Federico Sampedro, Ph.D. Hospital Sant Pau, Barcelona, Spain
1988 - 1989	Aida Esteves, Ph.D. LNETI, Lisbon, Portugal

Sponsorship of Graduate Students:

1988 - 1989	Kiumars Vadieli, Advisory Committee University of Houston School of Pharmacy
1988 - 1989	Amita Joshi, Supervisory Committee UT College of Pharmacy, Austin, Texas
1992 - 1993	Kishor Wasan, Supervisory Committee Graduate School of Biomedical Sciences UT Health Science Center, Houston, Texas
1993 - 1995	Nouri Neamati, Supervisory Committee Graduate School of Biochemical Sciences UT Health Science Center, Houston, Texas
1993 - 1995	Geneva Chen, Supervisory Committee University of Houston School of Pharmacy, Houston, Texas
1993 - 1997	Saeed Khan, Advisory Committee Graduate School of Biomedical Sciences UT Health Science Center, Houston, Texas
1994 - 1997	Robert Kumi, Co-Chairman, Supervisory Committee University of Houston School of Pharmacy, Houston, Texas "Tumor Targeting of Anthracyclines"
1997 - 1998	Xi Zhu, Advisory Committee Graduate School of Biomedical Sciences

UT Health Science Center, Houston, Texas

Grant Support for the Past 10 Years as Principal Investigator:

a. Peer Reviewed

1. **July 1989 - June 1992**
NIH 1R01 CA45423
Development and preclinical evaluation of new lipophilic cisplatin analogues entrapped in liposomes
\$350,201
2. **January 1991 - December 1993**
NIH 1R01 CA50270
Anthracycline antibiotics with high affinity for lipid membranes
\$677,528
3. **September 1993 - August 1995**
NIH 1R03 CA58342
Treatment of Malignant Pleural Effusions with Intrapleural Administration of L-NDDP
\$141,842
4. **January 1994 - December 1995**
Texas Higher Education Coordinating Board Advanced Technology Grant (000015-83)
Tumor targeting of non cross-resistant anthracycline antibiotics
\$179,920 direct cost
5. **January 1994 - December 1997**
NIH 1R01 CA50270-04 (competing renewal)
Annamycin: mechanisms of action and optimization of tumor targeting
\$1,195,860
6. **July 1996 - June 1998**
NIH 1R21 CA67038
Treatment of Dox resistant breast cancer with liposomal-Annamycin
\$285,956
Declined because of overlap with U.S. Army Grant
7. **July 1996 - June 1998**
ACS # DHP - 175
Development of L-NDDP for the treatment of cisplatin-resistant ovarian carcinoma
\$200,000 (Declined because of overlap with NIH 1R01 CA 64096)
8. **July 1996 - June 2000**
NIH 1R01 CA64096
Development of L-NDDP for the treatment of cisplatin-resistant ovarian carcinoma
\$607,016
9. **September 1996 - August 2000**
US Army Breast Cancer Research Grant DAMD 17-96-C-6105

04/22/02

Treatment of metastatic breast carcinoma refractory to doxorubicin with liposomal-
Annamycin
\$538,401

10. October 1996 - September 2000

FDA Office of Orphan Products FDR-001234-01
Phase II study of intrapleural L-NDDP for patients with malignant pleural mesothelioma
\$725,438

11. July 1999- June 2002

NIH 2 R01 63653 (Burke)
Long-circulating liposomal camptothecins
\$665,965
co-P.I. and P.I. of NYU subcontract, \$164,702

12. March 2000- February 2004

NIH 1 R01 CA86845-01. Aerosolized cationic lipid/p53 gene therapy in patients with lung
cancer.
\$1,692,911

13. September 2000-August 2005

NIH 1 K24 CA 84119. Mid-career Clinical Investigator Award in Patient-Oriented Research.
Innovative tumor-targeted therapies for lung cancer
\$628,100

14. June 2001-May 2005

NIH 1 RO1 CA 91784-01
Synergism between chemotherapy and anti-EGFR antibody C225 in lung cancer
\$1,485,000

15. September 2001-August 2003

NIH 2 R42 CA 75761-02
Long-circulating Liposomal Camptothecins
\$150,000
Sub-contract with Tigen Pharmaceuticals

b. Commercial

1. 1985 - 1988

The Liposome Company: Development of new lipophilic cis-platinum analogues
encapsulated in liposomes (Khokhar AR, Lopez-Berestein G, co-PI's)
\$650,603

2. 1988 - 1989

The Liposome Company: Phase I clinical and Pharmacology study of liposome entrapped
cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II)
\$288,841

3. July 1988 - June 1991

Argus Pharmaceuticals : Development of liposomal products.

Principal investigators: Lopez-Berestein G, Mehta R, Mehta K, **Perez-Soler R**,
and Priebe W
\$1,146,123

4. **July 1991 - 1997**
Aronex Pharmaceuticals: Development of liposomal-anthracyclines.
\$110,688/year
5. **February 1992 - June 1994**
SmithKline Beecham: Phase II Study of Topotecan in non-small cell lung cancer
\$120,000
6. **July 1993 - December 1994**
Argus Pharmaceuticals: Preclinical development of stable liposomal formulations of
lipophilic and non-cross resistant platinum compounds
\$139,750/year
7. **June 1994 - December 1997**
SmithKline Beecham: Phase II Study of Topotecan in squamous cell carcinoma
of the lung
\$69,000
8. **August 1994 - August 1995**
SmithKline Beecham: An open-label, multicenter, non-comparative study of Topotecan as
single agent, second line therapy in patients with small cell lung cancer
\$18,000
9. **January 1996 - January 1997**
SmithKline Beecham: An open-label, randomized study of Topotecan vs. CAV in patients
with small cell lung cancer
\$30,000
10. **April 1996 - November 1996**
Sequus Pharmaceuticals: An open-label, multicenter study of Doxil in refractory or relapsing
patients with advanced small cell carcinoma of the lung
\$45,000
11. **May 1996 - November 1996**
DuPont Merck: Phase II study of DMP-840 in patients with non-small cell lung cancer
\$30,000
12. **September 1996 - July 1998**
Sequus Pharmaceuticals: Phase II study of Doxil in patients with malignant mesothelioma
\$35,000
13. **September 1997 - July 1998**
Imclone Systems, Inc.: Phase I study of anti-EGFR monoclonal antibody C225 in
combination with cisplatin in patients with head and neck cancer
\$75,000

14. **December 1997 – July 1998**
SmithKline Beecham: Phase I study of weekly Topotecan and Gemcitabine
\$70,000
15. **April 1999 – April 2000**
EntreMed, Inc.: 2-Methoxyestradiol: a novel endogenous chemotherapeutic and antiangiogenic agent
\$15,000
16. **July 1999**
Imclone Systems, Inc: Neoadjuvant treatment with taxotere, carboplatin and C225 in patients with stage IIIA NSCLC
\$210,000
17. **March 2000**
Pfizer Pharmaceuticals Inc./OSI Pharmaceuticals Inc.: Phase II study of CP-358774 in patients with recurrent head and neck cancer.
\$36,000
18. **March 2000**
Pfizer Pharmaceuticals, Inc./OSI Pharmaceuticals Inc.: Phase II study of CP-358774 in patients with recurrent non-small cell lung cancer.
\$125,000
19. **January 2001**
OSI Pharmaceuticals, Inc.
Determinants of Sensitivity to OSI-774
\$120,000

Peer Reviewed Grant Support for the Last 10 Years as Co-Investigator:

June 1991 - July 1994

NIH NO1 CM 97 610

Clinical Trials of Monoclonal Antibodies, Immunoconjugates and other targeting agents (CTEP) (J.L. Murray, M.D., P.I.)

\$328,210/year

Phase I study of anti EGFR monoclonal antibody RG83852 in patients with NSCLC (R. Perez-Soler, Protocol Chairman)

July 1992 - June 1995

NIH 1RO1 CA55320-01

Target specificities of deaminated anthracyclines (W. Priebe, Ph.D., P.I.)

\$167,200/year

September 1992 - September 1994

NIH 1RO3 CA58752-01

In vitro correlates of drug sensitivity in lung cancer (B.S. Glisson, M.D., P.I.)

\$47,989

March 1993 - February 1994

Robert H. Winn Foundation

Phase II clinical trial of liposomal cisplatin analog in cats in oral squamous cell carcinoma
(Leslie E. Fox, DVM, P.I., University of Florida, Gainesville, FL)

\$12,900

February 1997 - January 2000

NIH 1 R01 CA 73018-01

Chemosensitization of NSCLC through signal transduction

Nicholas J. Donato, Principal Investigator

\$603,000

Patents:

a. Issued

1. **Perez-Soler R, Priebe W, Lopez-Berestein G**
Liposome compositions of anthracycline derivatives.
U.S. Patent 4,863,739
Issued September 5, 1989
2. **Khokhar AR, Lopez-Berestein G, Perez-Soler R**
Hydrophobic cis-platinum complexes efficiently incorporated into liposomes.
U.S. Patent 5,041,581
Issued August 20, 1991
3. **Khokhar AR, Lopez-Berestein G, Perez-Soler R**
Hydrophobic cis-platinum complexes efficiently incorporated into liposomes.
U.S. Patent 5,117,022
Issued May 22, 1992
4. **Priebe W, Perez-Soler R**
Esters of 3'-desamino-doxorubicin, liposomal compositions thereof,
and methods for their use.
U.S. Patent 5,132,290
Issued July 21, 1992
5. **Khokhar AR, Lopez-Berestein G, Perez-Soler R**
Hydrophobic cis-platinum complexes efficiently incorporated into liposomes.
U.S. Patent 5,178,876
Issued January 12, 1993
6. **Khokhar AR, Lopez-Berestein G, Perez-Soler R**
Hydrophobic cis-platinum complexes efficiently incorporated into liposomes.
U.S. Patent 5,186,940
Issued February 16, 1993
7. **Perez-Soler R, Khokhar AR, Han I**

Stable liposomal formulations of lipophilic platinum compounds

U.S. Patent 5,384,127

Issued, January 24, 1995

8. Priebe W, Skibicki P, **Perez-Soler R**
Anthracyclines with unusually high activity against cells resistant to doxorubicin and analogs
US Patent 5,625,043
Issued: April 29, 1997
9. Mehta K, **Perez-Soler R**, Lopez-Berestein G, Lenk RP, Hayman A.
Formulation and use of carotenoids in the treatment of cancer
US Patent 5,811,119
Issued: September 22, 1998
European Patent 0621773
Issued: November 25, 1998
10. Sugarman S, Poirot K, **Perez-Soler R**.
The liposomal entrapment of camptothecin.
US Patent 5,834,012
Issued: November 10, 1998
11. Priebe W, Chaires JB, Przewloka T, Fokt I, **Perez-Soler R**.
Bis-anthracyclines with high activity against doxorubicin-resistant tumors.
US Patent 5,874,412
Issued: February 23, 1999
12. Zou Y, Priebe W, **Perez-Soler R**.
Submicron liposome suspensions obtained from preliposome lyophilizates.
US Patent 5,902,604
Issued: May 11, 1999

b. Pending Patent Office Action

1. European Patent Application 485,143 (1992)
Cruz ME, Jorge JCS, Martins MBF, Gaspar MHG,
Simoes ACE, **Perez-Soler R**.
Liposomal compositions containing (palmitoyl) L-asparaginase, and processes for their production.
2. **Perez-Soler R**, Khokhar AR.
Liposomal formulations of diamminocyclohexane platinum (II) complexes
Serial No. 08/764,095
Filed December 6, 1996
3. Zou Y, **Perez-Soler, R**.
Gene therapy of tumors using a non-viral delivery system
Filed, January 6, 1998
4. **Perez-Soler R**.

In vivo chemosensitivity screen for human tumors
Filed April 26, 2000

5. Kelman CD, Perez-Soler, R.
Cryogenic and ultrasonic system and method of use in treating and removing tissue
Filed October 5, 2000

Investigational New Drug Exemptions (IND) Granted for New Anticancer Agents Developed:

1. February 1988
Cis-bis-neodecanoato-1,2-diaminocyclohexane platinum (II)
Sponsor: University of Texas M. D. Anderson Cancer Center
IND # 30,984

November 1998
Sponsor: New York University School of Medicine
IND # 57,177

2. December 1994
Annamycin
Sponsor: University of Texas M. D. Anderson Cancer Center
IND #46,869

Invited Lectures and Sessions Chaired (Selection):

1. May 1987
Development and preclinical evaluation of new lipophilic cisplatin analogues incorporated into liposomes.
Third Princeton Liposome Conference, Princeton, NJ
2. June 1987
Design of lipophilic cisplatin analogues for liposome incorporation.
FASEB Research Conference on Targeted Drug Delivery, Saxton Rivers, VT
3. February 1988
Design and development of liposome-dependent antitumor agents.
UCLA Symposium on "Liposomes in the Therapy of Infectious Diseases and Cancer",
Lake Tahoe, CA
4. November 1988
Design of drug-drug carrier complex
Third Annual Meeting, American Association of Pharmaceutical Scientists, Orlando, FL
5. November 1988
Development of liposome-dependent platinum compounds
Chemotherapy Foundation Symposium VIII, New York, NY
6. January 1989
Design and trials with lipophilic derivatives of cytostatic agents

Conferences on Clinical and Experimental Cancerology, Institut Jules Bordet, Brussels, Belgium

7. May 1989

Phase I clinical study of L-NDDP

Fourth Princeton Liposome Conference, Princeton, NJ

8. January 1990

Anti-cancer agents encapsulated in liposomes

Grand Rounds

Kenneth Norris Jr. Cancer Center

University of Southern California, Los Angeles, CA

9. February 1990

The use of liposomes as carriers of platinum complexes as a novel approach in oncology
First International Conference on Platinum Complexes and Liposomes in the Treatment
of Cancer

Hospital de Sant Pau, Barcelona, Spain

10. December 1990

Development of lipophilic anticancer agents for liposome delivery

Liposomes in Drug delivery: 21 Years On

The School of Pharmacy, University of London, London, UK

11. January 1991

Pharmacologic studies with new liposome-entrapped cisplatin derivatives

Sixth International Symposium on Platinum and Other Metal Coordination Compounds
in Cancer Chemotherapy, San Diego, CA

12. March 1991

Use of liposomes as carriers of antitumor agents

University of Houston School of Pharmacy, Houston, TX

13. May 1991

Annual Meeting of the American Association for Cancer Research (AACR)

Co-Chairman of Poster Discussion Session on Regional Drug Delivery, Houston, TX

14. November 1991

Targeting hematological malignancies

Annual Meeting of the Leukemia Society of America, St. Louis, MO

15. April 1992

Development of lipophilic antitumor agents

University of Florida, Gainesville, FL

16. May 1992

Co-Chairman of Minisymposium on liposomes in drug delivery

Annual Meeting of the American Association of Cancer Research (AACR), San Diego, CA

17. March 1993

Use of drug carriers to ameliorate anticancer properties of anthracycline antibiotics

2nd Anthracycline Antibiotics Symposium
American Chemical Society National Meeting, Denver, CO

18. May 1993

Co-Chairman of poster discussion on growth factors and chemotherapy
Annual Meeting of the American Association for Cancer Research (AACR), Orlando, FL

19. December 1993

Mechanistic studies with non-cross resistant lipophilic platinum compounds and anthracyclines designed for liposome delivery.
Liposomes in drug delivery: the nineties and beyond
The School of Pharmacy, University of London, London, UK

20. March 1994

The use of liposomes as carriers of antitumor agents
Liposomes as biomembrane models: principles, applications, and interactions with metal ions and biological molecules
European Science Foundation Workshop, Jerez, Spain

21. March 1994

Strategies for drug targeting to tumors
University of Utrecht School of Pharmacy, Utrecht, The Netherlands

22. March 1994

Development of new antitumor agents: from the synthesis laboratory to clinical trials
Ohio State University College of Pharmacy, Columbus, OH

23. October 1994

Pharmacology and biological studies with Annamycin incorporated in long-circulating liposomes
Conference on liposomes in biomedical research
Max-Delbruck-Centrum for Molekulare Medizin
Berlin, Germany

24. March 1995

Liposomes: an opportunity to improve cytotoxic anticancer therapy
A liposome birthday conference
Cambridge, UK

25. March 1996

Preclinical Development of Annamycin
3rd Anthracycline Antibiotics Symposium
211th American Chemical Society National Meeting
New Orleans, LA

26. March 1996

Chairman, Session on New Anthracyclines in Clinical Trials
3rd Anthracycline Antibiotics Symposium
211th American Chemical Society National Meeting
New Orleans, LA

27. June 1996
New drugs in advanced lung cancer: experience of the M. D. Anderson Cancer Center
New Trends in Oncology
Istituto Nazionale per lo Studio e la Cura dei Tumori
Napoli, Italy
28. July 1996
New Experimental Therapies in Lung Cancer
European Summer Course on Advances in Oncology
San Sebastian, Spain
29. October 1996
Aerosolized lipofection for the correction of genetic defects in bronchial premalignancy
V Oncogene Symposium (Spanish Association Against Cancer)
San Sebastian, Spain
30. October 1996
Liposomes as carriers of anticancer therapies
University of Kentucky College of Pharmacy
Lexington, KY
31. November 1996
New therapies for lung cancer
II Jornadas Oncologicas Nacionales de SOLCA
Guayaquil, Ecuador
32. February 1997
Genetic replacement strategies in the treatment of premalignant bronchial lesions
M.D. Anderson new drug studies in lung cancer
II Andorran Congress on Lung Cancer
Andorra
33. March 1997
Chairman, Supportive Care Session
First E.J. Freireich Symposium on Foundations of Clinical Cancer Research
M. D. Anderson Cancer Center
Houston, TX
34. June 1997
Gene Therapy - Cancer Applications
IBC's Second International Conference on Delivery and Design of Genetic Medicines
Annapolis, MD
35. November 1997
Topoisomerase I Inhibitors in Lung Cancer
Fall Solid Tumor Conference
Ft. Myers, FL
36. November 1997
Clinical Oncology Grand Rounds

Topoisomerase I Inhibitors in Lung Cancer
UT Southwestern Medical School
Dallas, TX

37. November 1997
New Directions in Lung Cancer Gene Therapy
First International Symposium on Advances in Lung Cancer
Hospital Ramon y Cajal
Madrid, Spain

38. February 1998
New Initiatives in Lung Cancer Therapy Research
Kaplan Comprehensive Cancer Center
New York University
New York, NY

39. February 1998
Advances in Lung Cancer Therapy
Sylvester Comprehensive Cancer Center
University of Miami
Miami, FL

40. May 1998
Camptothecins in the Treatment of Small Cell Lung Cancer
Annual Meeting of the Oncology Nursing Society
San Francisco, CA

41. October 1998
Co-chairman
Session on Basic and Applied Research of Topoisomerase Inhibitors
9th Conference on DNA Topoisomerases in Therapy
New York University School of Medicine
New York, NY

42. October 1998
Advances in lung cancer therapy
Clinical Oncology Grand Rounds
Dartmouth Hitchcock Medical Center
Lebanon, NH

43. November 1998
Emerging new drugs for lung cancer
Focus on Tumors: Lung & Thoracic
Sylvester Comprehensive Cancer Center
University of Miami
Miami, FL

44. December 1998
Advances in the Management of Lung Cancer
Medicine Grand Rounds

Albany Medical College
Albany, NY

45. March 1999

Use of Drug Carriers to Deliver Anthracycline Antibiotics
Anthracycline Antibiotics Symposium: "From the Bench to the Clinic"
217th American Chemical Society National Meeting
Anaheim, CA

46. March 1999

Clinical and Mechanistic Studies with L-NDDP
8th International Symposium on Platinum and Other Metal Coordination
Compounds in Cancer Chemotherapy
Oxford, UK

47. April 1999

Co-Chairman
Poster Discussion Session on Advances in Drug Delivery and Tumor Vascular Targeting
Annual Meeting of the American Association for Cancer Research
Philadelphia, PA

48. June 1999

Delivery of Anticancer Lipophilic Drugs by Means of Liposomes
The 26th International Symposium on Controlled Release of Bioactive Materials
Boston, MA

49. July 1999

New Treatment Strategies in Small Cell Lung Cancer
Clinical Oncology Grand Rounds
University of California at San Francisco
San Francisco, CA

50. July 1999

Use of heterotransplants to predict lung cancer chemosensitivity
New molecular therapies for lung cancer
Universidad Internacional Menendez Pelayo
Santander, Spain

51. October 1999

Clinical Oncology Grand Rounds
Advances in lung cancer therapy
Mount Sinai School of Medicine
New York, NY

52. November 1999

New regimens for Small Cell Lung Cancer
Chemotherapy Foundation Symposium
New York, NY

53. November 1999

Topoisomerase I inhibitors in the treatment of non-small cell lung cancer
6th Hong Kong International Cancer Conference
Hong Kong

54. December 1999
Use of large liposomes for the treatment of intracavitary cancers
Liposome advances: progress in drug and vaccine delivery
University of London, London, UK

55. March 2000
Advances in non-small cell lung cancer
Grand Rounds
Division of Medical Oncology
State University of New York at Syracuse
Syracuse, NY

56. March 2000
Treatment of small cell lung cancer
Third Lung Cancer Symposium
Miami, FL

57. March 2000
Advances in the treatment of small cell lung cancer
Grand Rounds, Hematology/Oncology
University of Virginia
Charlottesville, VA

58. March 2000
Chairman
Clinical Trials Session
New York Academy of Sciences Conference: "The Camptothecins"
Arlington, VA

59. November 2000
New advances in lung cancer treatment
University of Texas at San Antonio
San Antonio, TX

60. December 2000
New initiatives in lung cancer therapy research
Albert Einstein School of Medicine
Bronx, NY

61. February 2001
National Cancer Institute-CTEP
Phase I Investigators Meeting
Effects of PS341 on cell cycle and Bcl-2
Rockville, MD

62. May 2001

Advances in lung cancer therapy
MD Anderson Cancer Center
Houston, TX

63. October 2001
Fifth Annual Advances in Solid Tumors
Fall Oncology Conference
EGFR inhibitors in lung cancer
Amelia Island, FL

64. October 2001
11th Conference on DNA Topoisomerases in Therapy
Novel drug delivery systems for camptothecin drugs
New York University School of Medicine

65. October 2001
EGFR tyrosine kinase inhibitors
Grand Rounds
M.D. Anderson Cancer Center
Houston, TX

66. December 2001
Liposome Advances
Lipid-based formulations of anticancer agents for the treatment of lung cancer by inhalation
The School of Pharmacy, University of London
London, UK

BIBLIOGRAPHY

I. Articles in Peer Review Journals

1. Tornos MP, **Perez-Soler R**, Fernandez-Perez R: Lactobacillus casei endocarditis in tricuspid atresia. *Chest* 77:713, 1980.
2. **Perez-Soler R**, Esteban R, Guardia J: Urinary monoclonal immunoglobulin excretion in multiple myeloma. *Ann Int Med* 94:140, 1981.
3. **Perez-Soler R**, Tornos C: γ glutamyltranspeptidase in alcoholism. *Lancet* 1:894, 1981.
4. **Perez-Soler R**, Cervantes M, Segura RM, Esteban R, Pascual C, Guardia J: Serum glutamate dehydrogenase in alcoholic liver disease. *Br Med J* 283:1332, 1981.
5. **Perez-Soler R**, Pico M, Esteban R, Cervantes M, Guardia J: ABC of alcohol: platelet dysfunction in alcoholism. *Br Med J* 284:510, 1982.
6. Cervantes M, **Perez-Soler R**, Segura RM, Esteban R, Pascual C: La glutamate deshydrogenase dans les maladies du foie et des voies biliaires. *Nouv Presse Med* 11:2642, 1982.
7. **Perez-Soler R**, Sanz Alonso MA, Jaen Campos A, Tornos C, Martinez Dominguez J, Esteban Mur R, Guardia Masso J, Triginer J: Tuberculosis y pseudoleucemia: estudio de 4 pacientes. *Med Clin (Barc)* 80:884-7, 1983.
8. Buti M, **Perez-Soler R**, Cervantes M, Ruiz-Marcellan C, Genesca J, Esteban R, Guardia J: Afeccion pleuro-pulmonar como unica manifestacion de la macroglobulinemia de Waldenstrom. *Med Clin (Barc)* 82:320-322, 1984.
9. **Perez-Soler R**, Cabanillas F: Avances en el conocimiento de la inmunobiologia de la enfermedad de Hodgkin. *Neoplasia* 1:63-7, 1984.
10. **Perez-Soler R**, McLaughlin P, Velasquez WS, Hagemeister FB, Zornoza J, Manning JT, Fuller LM, Cabanillas F: Clinical features and results of management of superior vena cava syndrome secondary to lymphoma. *J Clin Oncol* 2:260-6, 1984.
11. Merino J, **Perez-Soler R**, Luna M, Cabanillas F: Benign fibrous histiocytoma in Hodgkin disease. *Cancer Invest* 2:347-50, 1984.
12. **Perez-Soler R**, Lopez-Berestein G, Cabanillas F, McLaughlin P, Hersh EM: Superoxide anion ($O_2^{\cdot -}$) production by peripheral blood monocytes in Hodgkin disease and lymphoma. *J Clin Oncol* 3:641-645, 1985.
13. **Perez-Soler R**, Lopez-Berestein G, Kasi LP, Cabanillas F, Jahns M, Glenn H, Hersh EM, Haynie T: Distribution of ^{99m}Tc -labeled multilamellar liposomes in patients with Hodgkin disease. *J Nucl Med* 26:743-749, 1985.
14. **Perez-Soler R**, Esteban R, Allende E, Tornos Salomo C, Julia A, Guardia J: Liver involvement in multiple myeloma. *Am J Hematol* 20:25-29, 1985.
15. **Perez-Soler R**, Lopez-Berestein G, Jahns M, Wright K, Kasi LP: Distribution of radiolabeled multilamellar liposomes injected intralymphatically and subcutaneously. *Int J Nucl Med Biol* 12:261-266, 1985.
16. Murray JL, **Perez-Soler R**, Bywaters D, Hersh EM: Decreased adenosine deaminase (ADA) and 5'nucleotidase (5'NT) activity in peripheral blood T cells in Hodgkin's disease. *Am J Hematol* 21:57-66, 1986.
17. **Perez-Soler R**, Smith T, Cabanillas F: Central nervous system (CNS) prophylaxis with combined intravenous and intrathecal methotrexate (MTX) in diffuse lymphomas of aggressive histologic type. *Cancer* 57:971-977, 1986.
18. **Perez-Soler R**, Khokhar AR, Claringbold P, Kasi LP, Lopez-Berestein G: Effects on the monocyte-macrophage system and antitumor activity against L1210 leukemia of cis-bis-cyclophenetene-carboxylato-trans R,R-1,2-diaminocyclohexane platinum (II) encapsulated in multilamellar vesicles. *J Natl Cancer Inst* 77:1137-1143, 1986.
19. **Perez-Soler R**, Khokhar AR, Hacker MP, Lopez-Berestein G: Toxicity and antitumor

- activity of cis-bis-cyclopentene-carboxylato-1,2-diaminocyclohexane platinum (II) encapsulated in multilamellar vesicles. *Cancer Res* 46:6269-6273, 1986.
20. Lautersztain J, Perez-Soler R, Khokhar AR, Newman RA, Lopez-Berestein G: Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diamino-cyclohexane platinum (II). *Cancer Chemother Pharmacol* 18:93-97, 1986.
21. Perez-Soler R, Khokhar AR, Lautersztain J, Mitchell PA, Schmidt KL: Ultrastructural and freeze fracture localization of multilamellar liposomes containing a lipophilic cisplatin analogue in normal tissues and liver metastases of M5076 reticulosarcoma. *Cancer Drug Deliv* 4:75-88, 1987.
22. Perez-Soler R, Khokhar AR, Lopez-Berestein G: Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) encapsulated in multilamellar vesicles. *Cancer Res* 47:6462-6466, 1987.
23. Lautersztain J, Perez-Soler R, Turpin J, Khokhar AR, Siddik ZH, Schmidt K, Lopez-Berestein G: Cellular pharmacology of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diamino-cyclohexane platinum (II). *Cancer Res* 48:1300-1306, 1988.
24. Perez-Soler R, Yang LY, Drewinko B, Lautersztain J, Khokhar AR: Increased cytotoxicity and reversal of resistance to cisplatin with entrapment of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) in multilamellar lipid vesicles. *Cancer Res* 48:4509-4512, 1988.
25. Khokhar AR, Wright K, Siddik ZH, Perez-Soler R: Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery. *Cancer Chemother Pharmacol* 22:223-227, 1988.
26. Lautersztain J, Khokhar AR, Perez-Soler R: Antitumor activity of liposomal cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane platinum (II) against L1210 leukemia and metastases of M5076 reticulosarcoma. *J Liposome Res* 1:1-13, 1988.
27. Khokhar AR, Al-Baker S, Perez-Soler R: Toxicity and antitumor activity of hydrophobic diammine and diaminocyclohexane platinum complexes entrapped in multilamellar vesicles. *Anticancer Drug Design* 3:177-183, 1988.
28. Khokhar AR, Al-Baker S, Krakoff IH, Perez-Soler R: Toxicity and antitumor activity of cis-bis-carboxylato (trans-R,R-1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes, a new series of lipid-soluble drugs. *Cancer Chemother Pharmacol* 23:219-224, 1989.
29. Perez-Soler R, Lautersztain J, Stephens LC, Wright K, Khokhar AR: Pharmacology and toxicity of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) in mice and dogs. *Cancer Chemother Pharmacol* 24:1-8, 1989.
30. Perez-Soler R: Liposomes as carriers of antitumor agents. Towards a clinical reality. *Cancer Treat Rev* 16: 67-82, 1989.
31. Vadieli K, Lopez-Berestein G, Perez-Soler R, Luke David R: Formulation and *in vitro* evaluation of liposomal-cyclosporine. *Int J Pharmaceutics* 57:133-138, 1989.
32. Vadieli K, Perez-Soler R, Lopez-Berestein G, Luke David R: Pharmacokinetic and pharmacodynamic evaluation of liposomal-cyclosporine. *Int J Pharmaceutics* 57:125-131, 1989.
33. Perez-Soler R, Khokhar AR, Lautersztain J, Al-Baker S, Karen Francis, Macias-Kiger D, Lopez-Berestein G: Clinical development of liposomal-platinum. *J Liposome Research* 1 (4) 447-459, 1990.
34. Perez-Soler R, Lopez-Berestein G, Lautersztain J, Al-Baker S, Francis K, Macias-Kiger D, Raber Martin N, Khokhar AR: Phase I clinical and pharmacology study of liposome-

- entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II). *Cancer Res* 50:4254-4259, 1990.
35. **Perez-Soler R**, Priebe W: Anthracycline antibiotics with high liposome entrapment: structural features and biological activity. *Cancer Res* 50:4260-4266, 1990.
36. Priebe W, Neamati NM, **Perez-Soler R**: 3'-Hydroxyesorubicin. Synthesis and biological activity. *J Antibiotics* 43:838-846, 1990.
37. Khokhar AR, Al-Baker S, Brown T, **Perez-Soler R**: Chemical, toxicological, and antitumor activity studies on a series of lipid soluble single isomer 1,2-diaminocyclohexane-platinum (II) complexes entrapped in liposomes. *J Med Chem* 34:325-329, 1991.
38. Priebe W, Grynkiewicz G, Neamati NM, **Perez-Soler R**: A facile method for preparation of 3'-thio sugars and 3'-thio glycals. Synthesis of 3'-mercapto-3'-deamino doxorubicin. *Tetrahedron Letters* 2:3313-3316, 1991.
39. Vadie K, Lopez-Berestein G, **Perez-Soler R**, Luke DR: Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine. *Drug Metabolism and Disposition* 19:1147-1151, 1991.
40. Priebe W, Neamati NM, **Perez-Soler R**: 3'-hydroxy-esorubicin halogenated at C-2'. *J Antibiotics* 45:386-393, 1992.
41. Khokhar AR, Al-Baker S, **Perez-Soler R**: Toxicity and efficacy studies on a series of lipid-soluble di-neodecanoato (trans-R,R- and -S,S-1,2- diaminocyclohexane) platinum (II) complexes entrapped in liposomes. *Anticancer Drugs* 3:95-100, 1992.
42. Zou Y, Horikoshi I, Ueno M, Gu X, **Perez-Soler R**: Targeting of liver tumors with the administration of liposomal doxorubicin into the hepatic artery. *Int J Cancer* 51:232-237, 1992.
43. Sugarman S, **Perez-Soler R**: Liposomes in the treatment of malignancy: A clinical review. *Critical Reviews in Oncology/Hematology* 12:231-242, 1992.
44. Al-Baker S, **Perez-Soler R**, Khokhar AR: Synthesis and biological studies of new lipid-soluble cisplatin analogues entrapped in liposomes. *J Inorg Biochem* 47:99-108, 1992.
45. **Perez-Soler R**, Priebe W: Liposomal formulation and antitumor activity of 14-O-palmitoyl hydroxyrubicin. *Cancer Chemother Pharmacol* 30:267-271, 1992.
46. Vadie K, Siddik ZH, Khokhar AR, Al-Baker S, Sampedro F, **Perez-Soler R**: Pharmacokinetics of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) and cisplatin administered IV and IP in the rat. *Cancer Chemother Pharmacol* 30:365-369, 1992.
47. **Perez-Soler R**, Khokhar AR: Lipophilic cisplatin analogues entrapped in liposomes: Role of intra-liposomal drug activation in biological activity. *Cancer Res* 52:6341-6347, 1992.
48. Zou Y, Horikoski I, Kosagi T, Gu X, **Perez-Soler R**: Organ distribution and antitumor activity of free and liposomal doxorubicin administered into the hepatic artery. *Cancer Chemother Pharmacol* 31:313-318, 1993.
49. Priebe W, Van NT, Burke TG, **Perez-Soler R**: Removal of the basic amino group at position 3' from doxorubicin overcomes multidrug resistance and decreases cardiotoxicity. *Anticancer Drugs* 4:37-48, 1993.
50. Ling YH, Priebe W, Yang LY, Burke TG, Pommier Y, and **Perez-Soler R**: In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by Annamycin, an anthracycline derivative with high affinity for lipid membranes. *Cancer Res* 53:1583-1589, 1993.
51. Ling YH, Priebe W, **Perez-Soler R**: Apoptosis induced by anthracycline antibiotics in P388 parental and multi-drug resistant cells. *Cancer Res* 53:1845-1852, 1993.

52. Zou Y, Priebe W, Ling YH, **Perez-Soler R**: Organ distribution and tumor uptake of Annamycin entrapped in multilamellar vesicles. *Cancer Chemother Pharmacol* 32:190-196, 1993.
53. Zou Y, Yamagishi M, Horikoshi I, Ueno M, Gu X, **Perez-Soler R**: Enhanced therapeutic effect against liver W256 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery. *Cancer Res* 53:3046-3051, 1993.
54. Al-Baker S, **Perez-Soler R**, Khokhar AR: Synthesis and characterization of a series of hydrophobic antitumor bis (carboxylato) (1,2-diaminocyclohexane) platinum (II) complexes. *J Coord Chem* 29:1-6, 1993.
55. Cruz ME, Gaspar JS, Lopes F, Jorge A, **Perez-Soler R**: Liposomal L-asparaginase: in vitro evaluation. *Int J Pharmaceutics* 96:67-77, 1993.
56. Han I, Ling YH, Al-Baker S, Khokhar AR, **Perez-Soler R**: Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP) and cisplatin in A2780 and A2780/PDD cells. *Cancer Res* 53:4913-4919, 1993.
57. Ling YH, Priebe W, **Perez-Soler R**: Intrinsic cytotoxicity and reversal of multidrug resistance by Monensin in KB and KB/MDR cells. *Int J Oncol* 3:971-977, 1993.
58. Zou Y, Hayman A, Priebe W, **Perez-Soler R**: Quantitative analysis of the lipophilic doxorubicin analogue Annamycin in plasma and tissue samples by reverse-phase chromatography. *J Pharm Sciences* 82:1151-1154, 1993.
59. Ling YH, **Perez-Soler R**, Tseng NT: Effect of DNA topoisomerase inhibitor, 10-hydroxy camptothecin, on structure and function of nuclei and nuclear matrix in bladder carcinoma MBT-2 cells. *Anticancer Res* 13:1613-1618, 1993.
60. Fossella FV, Lee JS, Murphy WK, Lippman S, Calayag M, Pang A, Chasen M, Shin D, Glisson B, Benner S, Huber M, **Perez-Soler R**, Raber M, Hong WK: Phase II study of docetaxel (Taxotere) for recurrent or metastatic non-small cell lung cancer. *J Clin Oncol* 12: 1238-1244, 1994.
61. **Perez-Soler R**, Francis K, Al-Baker S, Pilkievicz F, Khokhar AR: Preparation and characterization of a liposomal preparation containing a lipophilic cisplatin derivative for clinical use. *J Microencapsulation* 11:41-54, 1994.
62. Sampedro F, Partika J, Santalo P, Molins-Pujol AM, Bonal J, **Perez-Soler R**: Liposomes as carriers of different new lipophilic antitumor drugs. A preliminary report. *J Microencapsulation* 11:309-318, 1994.
63. Zou Y, Ling YH, Van NT, Priebe W, **Perez-Soler R**: Antitumor activity of the lipophilic and partially non-cross resistant anthracycline annamycin entrapped in liposomes. *Cancer Res* 54:1479-1484, 1994.
64. **Perez-Soler R**, Han I, Al-Baker S, Khokhar AR: Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkylcarboxylate leaving groups. *Cancer Chemother Pharmacol* 33:378-384, 1994.
65. Han I, Nguyen T, Yang L-Y, Khokhar AR, **Perez-Soler R**: Cellular accumulation and DNA damage induced by liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP) in LoVo and LoVo/PDD cells. *Anticancer Drugs* 5:64-68, 1994.
66. **Perez-Soler R**, Donato NJ, Shin DM, Rosenblum MG, Zhang HZ, Tornos C, Brewer H, Chan JC, Lee JS, Hong WK, Murray JL: Tumor epidermal growth factor receptor (EGFR) studies in patients with non-small cell lung and head and neck cancer treated with anti-EGFR monoclonal antibody RG 83852. *J Clin Oncol* 12:730-739, 1994.
67. **Perez-Soler R**, Zou Y, Ling YH, Priebe W: Use of liposomes to deliver lipophilic anthracyclines. *J Liposome Research* 4:555-573, 1994.
68. Fossella FV, Lee JS, Murphy WK, Lippman S, Calayag M, Pang A, Chasen M, Shin D,

- Glisson B, Benner S, Huber M, **Perez-Soler R**, Raber M, Hong WK: Phase II study of docetaxel (Taxotere) for recurrent or metastatic non-small cell lung cancer. *J Clin Oncol* 12:1238-1244, 1994.
69. Han I, Ling YH, Khokhar AR, **Perez-Soler R**: Cell death and DNA fragmentation induced by liposomal platinum (II) complex, L-NDDP in A2780 and A2780/PDD cells. *Anticancer Res* 14:421-426, 1994.
70. **Perez-Soler R**, Ling YH, Zou Y, Priebe W: Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells. *Cancer Chemother Pharmacol* 34:109-118, 1994.
71. Jorge JCS, **Perez-Soler R**, Morais JG, Cruz MEM: Liposomal palmitoyl-L-Asparaginase: characterization and biological activity. *Cancer Chemother Pharmacol* 34:230-234, 1994.
72. Solary E, Ling YH, **Perez-Soler R**, Priebe W, Pommier Y: Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. *Int J Cancer* 58:85-94, 1994.
73. Shin DM, Holoye PY, Forman A, Winn R, **Perez-Soler R**, Dakhil S, Rosenthal J, Raber MN, Hong WK: Phase II clinical trial of Didemnin B in previously treated small cell lung cancer. *Inv New Drugs* 12:243-249, 1994.
74. Huber MH, Benner SE, Lippman SM, Dimery IW, Shirinian M, **Perez-Soler R**, Guillory-Perez C, Hong WK: Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck. *Inv New Drugs* 12:327-331, 1994.
75. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, **Perez-Soler R**, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Hong WK, Raber M: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. *J Clin Oncol* 13:645-651, 1995.
76. Ling YH, Zou Y, Priebe W, **Perez-Soler R**: Partial overcoming of multidrug resistance by Annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells. *Int J Cancer* 61:402-408, 1995.
77. Zou Y, Ling YH, Reddy S, Priebe W, **Perez-Soler R**: Effect of vesicle size and lipid composition on the *in vivo* tumor selectivity and toxicity of the non-cross resistant anthracycline Annamycin incorporated in liposomes. *Int J Cancer* 61:666-671, 1995.
78. Wasan K, **Perez-Soler R**: The distribution of free and liposomal Annamycin in human plasma is regulated by triglyceride distribution and not lipid transfer protein. *J Pharm Sci* 84:1094-1100, 1995.
79. Zou Y, Priebe W, Stephens LC, **Perez-Soler R**: Preclinical toxicity of liposome-incorporated Annamycin: Selective bone marrow toxicity with lack of cardiotoxicity. *Clin Cancer Res* 1:1369-1374, 1995.
80. Li S, Khokhar AR, **Perez-Soler R**, Huang L: Improved antitumor activity of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) entrapped in long circulating liposomes. *Oncology Research* 7:611-617, 1995.
81. Sugarman SM, Zou Y, Wassan K, Poirot K, Kumi R, Reddy S, **Perez-Soler R**: Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. *Cancer Chemother Pharmacol* 37:531-538, 1996.
82. **Perez-Soler R**, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Lee JS, Kemp BL, Lee J, Kane J, Robinson RA, Lippman SM, Kurie J, Huber MH, Raber MN, Hong WK: Phase II study of Topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. *J Clin Oncol* 14:503-513, 1996.
83. Mori A, Wu SP, Han I, Khokhar AR, **Perez-Soler R**, Huang L: *In vivo* antitumor activity of cis-bis-neodecanoato-trans-R,R-1,2 diaminocyclohexane platinum (II)

- formulated in long-circulating liposomes. *Cancer Chemother Pharmacol* 37:435-444, 1996.
84. Ling YH, El-Naggar AK, Priebe W, **Perez-Soler R**: Cell cycle dependent cytotoxicity, G2/M phase arrest, and disruption of P34^{cdc2}/cyclin B1 activity induced by Doxorubicin in synchronized P388 cells. *Mol Pharmacol*. 49:832-841, 1996.
 85. Gaspar MM, **Perez-Soler R**, Cruz MEM: Biological characterization of L-asparaginase liposomal formulations. *Cancer Chemother Pharmacol* 38:373-377, 1996.
 86. Consoli U, Priebe W, Ling Y-H, Mahadevia R, Griffin M, Zhao S, **Perez-Soler R**, Andreef M: The novel anthracycline Annamycin is not affected by P-glycoprotein-related multidrug resistance: Comparison with Idarubicin and Doxorubicin. *Blood* 88:633-644, 1996.
 87. **Perez-Soler R**, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, Hong WK: Treatment of patients with small cell lung cancer refractory to etoposide with the topoisomerase I poison Topotecan. *J Clin Oncol*. 14:2785-2790, 1996.
 88. Han I, Khokhar AR, **Perez-Soler R**: Intraliposomal conversion of lipophilic cis-bis-carboxylato-trans-R, R-1,2-diaminocyclohexane-platinum (II) complexes into cis-bis-dichloro-trans-R, R-1,2-diaminocyclohexane-platinum (II). *Cancer Chemother Pharmacol*. 39:17-24, 1996.
 89. Zou Y, Priebe W, **Perez-Soler**: Lyophilized liposome formulation of the non-cross resistant anthracycline Annamycin: Effect of surfactant on liposome formation, stability, and size. *Cancer Chemother Pharmacol*. 39:103-108, 1996.
 90. Fossella FV, Lippman SM, Shin DM, Tarese P, Calayag M, **Perez-Soler R**, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK: Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer. *J Clin Oncol*. 15(1):310-316, 1997.
 91. **Perez-Soler R**, Shin DM, Siddik ZH, Murphy Wk, Huber M, Lee JS, Khokhar AR, Hong WK: Phase I clinical and pharmacological study of liposome-entrapped NDDP (L-NDDP) administered intrapleurally in patients with malignant pleural effusions. *Clin Cancer Res* 3:373-379, 1997.
 92. Chaires JB, Leng F, Przewlaka T, Fokt I, Ling YH, **Perez-Soler R**, Priebe W: Structure-based design of a new bisintercalating anthracycline antibiotics. *J Med Chem*. 40:261-266, 1997.
 93. **Perez-Soler R**, Neamati N, Zou Y, Schneider E, Austin Doyle L, Andreeff M, Priebe W, Ling YH: Annamycin circumvents resistance mediated by the multidrug resistance protein (MRP) in breast MCF-7 and small cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. *Int J Cancer*. 71:35-41, 1997.
 94. Glisson BS, Lee JS, Palmer J, Fossella FV, Shin DM, Murphy WK, **Perez-Soler R**, Hong WK: Phase I-II study of cisplatin, ifosfamide, and prolonged oral etoposide in extensive small cell lung cancer. *Cancer* 82:301-308, 1998.
 95. Glisson BS, Komaki R, Yu R, Webster M, Fossella FV, Kurie JM, Lee JS, Murphy WK, **Perez-Soler R**, Shin DM, Schea R, Hong WK, Vadhan-Raj S: Integration of Filgastrim into chemoradiation for limited small cell lung cancer: a phase I study. *Int J Rad Oncol Biol Phys* 40:331-326, 1998.
 96. Ling YH, Consoli U, Tornos C, Andreef M, **Perez-Soler R**: Accumulation of cyclin B1, activation of cyclin B1-dependent kinase, and induction of programmed cell death in KB cells treated with Paclitaxel. *Int J Cancer*. 75:925-932, 1998.
 97. Fueyo J, Gomez-Manzano C, Puduvali VK, Martin-Duque P, **Perez-Soler R**, Levin VA, Yung WKA, Kyritsis AP: Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: Implications for therapy. *Int J Oncol*. 12:665-670, 1998.

98. Ling YH, Tornos C, **Perez-Soler R**: Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. *J Biol Chem* 273:18984-18991, 1998.
99. Zou Y, Zong G, Ling YH, Hao MM, Lozano G, Hong WK, **Perez-Soler R**: Effective treatment of early endobronchial cancer with the regional administration of liposome-p53 complexes. *J Natl Cancer Inst.* 90:1130-1137, 1998.
100. Ling YH, Yang Y, Tornos C, Singh B, **Perez-Soler R**: Paclitaxel-induced apoptosis is associated with expression and activation of c-mos gene product in human ovarian carcinoma SKOV3 cells. *Cancer Res.* 58:3633-3640, 1998.
101. Jiang JD, Davis AS, Middleton Kim, Ling YH, **Perez-Soler R**, Holland JF, and Bekesi GJ: 3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2 and induces apoptosis in tumor cells. *Cancer Res.* 58:5389-5395, 1998.
102. Fox LE, Toshach Katrina, Calderwood-Mays M, Khokhar AR, Kubilis P, **Perez-Soler R**, MacEwen EG: Evaluation of toxicosis of liposome-encapsulated cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) in clinically normal cats. *Am J Vet Res* 60:257-263, 1999.
103. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Merritt JA, Nguyen DM, Nesbitt JC, **Perez-Soler R**, Pisters K, Putnam Jr, JB, Richli W, Schrupp DS, Timmons T, Shin DM, Walsh GL, Waugh KA: Adenoviral-mediated p53 gene transfer in advanced non-small cell lung cancer. *J Natl Cancer Inst.* 91:763-771, 1999.
104. Glisson B, Kurie JM, **Perez-Soler R**, Winn RJ, Fox NJ, Murphy WK, Fossella FV, Lee JS, Pisters KMW, Shin DM, Hong WK: Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. *J Clin Oncol.* 17:2309-2315, 1999.
105. Shade RJ, Pisters KMW, Huber MH, Fossella FV, **Perez-Soler R**, Shin DM, Kurie J, Glisson B, Lippman S, Lee JS. Phase I study of paclitaxel administration by ten day continuous infusion. *Inv New Drugs.* 16:237-243, 1999.
106. Donato NJ, Perez M, Siddik Z, Ling YH, **Perez-Soler R**: EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cis-platinum sensitivity. *Clin Cancer Res.* 6:193-202, 2000.
107. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Savin M, Weill D, Shulkin A, Wait J, Ognoskie N, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, **Perez-Soler R**, Pisters KMW, Putnam JB, Richli WR, Shin MDM, Walsh GL, Merritt J, Roth J: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. *J Clin Oncol.* 18:609-622, 2000.
108. Ling YH, Zou Y, **Perez-Soler R**: Induction of senescence like phenotype and loss of paclitaxel sensitivity after wt p53 gene transfection in p53-null human NSCLC H358 cells. *Anticancer Res.* 20:693-702, 2000.
109. Zou Y, Zong G, Ling Y-H, and **Perez-Soler R**: Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. *Cancer Gene Ther* 7:683-696, 2000.
110. Fox LE, Rosenthal RC, King RR, Levine PB, Vail DM, Helfand SC, MacEwen G, **Perez-Soler R**, Calderwood-Mays M, Kurzman ID. Use of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal-cisplatin analogue, in cats with oral squamous carcinoma. *Am J Vet Res* 61:791-795, 2000.
111. Oh Y, **Perez-Soler R**, Fossella FV, Glisson B, Kurie J, Walsh GL, Truong M, and Shin DM: Phase II study of intravenous Doxil in malignant pleural mesothelioma. *Inv*

- New Drugs*.18:243-245, 2000.
112. McLean DS, Khokhar AR, Tyle P, **Perez-Soler R**: Intraliposomal chemical activation patterns of liposomal cis-bis-neodecanoato-trans-R, R-1,2-diaminocyclohexane platinum (II) (L-NDDP)- a potential antitumor agent. . *J. Microencapsulation*.17(3):307-322, 2000.
 113. McLean DS, Khokhar AR, **Perez-Soler R**: Neutron activation of NDDP, a liposomal platinum antitumor agent. *Cancer Biotherapy and Radiopharmaceutics*.15:253-259, 2000.
 114. Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, **Perez-Soler R**, Pisters KMW, Putnam JB, Jr., Schrump DS, Shin DM, Walsh GL and Roth JA. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumor injection of an adenovirus vector expressing wild type p53 (Ad-p53). *Cancer Gene Ther*. 7:530-536, 2000.
 115. **Perez-Soler R**, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J, Ling YH. Response and determinants of sensitivity to Paclitaxel in human non-small cell lung cancer (NSCLC) heterotransplants in nude mice. *Clin. Cancer Res*. 6:4932-4938, 2000.
 116. Booser D, **Perez-Soler R**, Zou Y, Priebe W, Hortobagyi G. Phase I clinical and pharmacology study of liposomal-Annamycin. *Cancer Chemother Pharmacol*. 86:427-432, 2000.
 113. Ling YH, Zhong Y, **Perez-Soler R**. Disruption of cell adhesion and caspase-mediated proteolysis of β , γ -catenins, and APC protein in paclitaxel-induced apoptosis. *Mol. Pharmacol*.59:593-603, 2001
 118. Shin DM, Donato NJ, **Perez-Soler R**, Shin HJC, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. *Clin Cancer Res*.7: 1204-1213,2001
 119. Zhong Y, Delgado Y, Gomez J, Lee SW, **Perez-Soler, R**. Loss of H-cadherin protein expression in human non-small cell lung cancer is associated with tumorigenicity. *Clin Cancer Res*. 7: 1683-1687, 2001.
 120. Ling YH, Donato NJ, **Perez-Soler R**: Sensitivity to cisplatin and topoisomerase I inhibitors is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. *Cancer Chemother Pharmacol*. 47(6):473-480, 2001
 121. Swisher SG, Roth JA, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, **Perez-Soler R**, Pisters KMW, Putnam JB, Jr., Schrump DS, shin DM and Walsh GL. Gene therapy in oncology: clinical challenges, needs and prospects as reflected in p53 gene replacement in NSCLC. *Semin. Oncol. In press*.
 122. Wu JY, Perez M, Ling YH, **Perez-Soler R**, Donato NJ: Defects in caspase 8 activation correlate with specific loss of apoptotic sensitivity to tumor necrosis factor in ME-180 cells. *Cell Death Diff. In press*.

II. Invited Articles:

1. **Perez-Soler R**: New drugs in cancer therapy. Highlights of the Sixth NCI-EORTC

- Symposium. *Drug News & Perspectives* 2:229-233, 1989.
2. **Perez-Soler R:** PLAT-23. *Drugs of The Future* 14:765-766, 1989.
3. **Perez-Soler R:** Liposomes: from the bench to the bedside. Highlights of the fourth Princeton Liposome Conference. *Drug News & Perspectives* 2:355-357, 1989.
4. **Perez-Soler R:** Liposomes as carriers of anticancer agents: current status and prospects. *Drug News & Perspectives* 3:287-291, 1990.
5. **Perez-Soler R:** Recent advances in cancer therapy. *Drug News & Perspectives* 3:444-445, 1990.
6. **Perez-Soler R:** Topotecan in the treatment of non-small cell lung cancer. *Semin Oncol* 24(S20):34-41, 1997.
7. **Perez-Soler R:** Topotecan: Expanding its efficacy beyond ovarian cancer. Editorial. *Semin Oncol* 24(S20):1-2, 1997.

III. Manuscripts Submitted for Publication:

1. Ling YH, Jiang JD, Liebes L, Elliott PJ, **Perez-Soler R.** Mechanisms of proteasome inhibitor PS-341-induced G2/M phase arrest and apoptosis in human non-small cell lung cancer H460 cells. *Clin Cancer Res*.
2. Ling YH, Jiang JD, Liebes L, Elliott PJ, **Perez-Soler R.** Characterization of Bcl-2 Protein phosphorylation and cleavage during proteasome inhibitor PS-341-induced apoptosis. *Mol Pharmacol*.
3. Zhong Y, Lopez L, **Perez-Soler R.** Exogenous expression of H-cadherin regulates contact inhibition, anchorage-independent growth and tumorigenicity. *Clin Cancer Res*
4. Ling YH, Jiang JD, Holland JF, **Perez-Soler R.** Arsenic trioxide induces microtubule stabilization, mitosis arrest, and apoptosis in human solid tumors. *Mol Pharmacol*

IV. Books and Chapters:

1. **Perez-Soler R, Khokhar AR, Lopez-Berestein G:** Development of lipophilic cisplatin analogues encapsulated in liposomes. In: *Liposomes as Drug Carriers*. (G Gregoriadis Ed) pp 401-417, John Wiley & Sons, Ltd, UK, 1988.
2. **Lopez-Berestein G, Perez-Soler R:** Prospects of Liposomes as Drug Carriers. In: *Anticarcinogenesis and Radiation Protection*. (PA Cerutti, OF Nygaard, and MG Simic Eds) pp 441-450, Plenum Press, New York and London, 1987.
3. **Perez-Soler R, Lopez-Berestein G, Khokhar AR:** Design and development of liposome dependent antitumor agents. In: *Liposomes in the treatment of infectious diseases and cancer*. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 89. (Lopez-Berestein G, I Fidler Eds) pp 59-69, Alan Liss, Inc., New York, NY, 1988.
4. **Perez-Soler R, Khokhar AR:** Development of liposome entrapped platinum compounds. From the bench to the bed side. Proceedings of the 16th International Congress of Chemotherapy, Jerusalem, Israel. pp 867.1-867.3, June 1989
5. **Perez-Soler R, Siddik ZH, Vadieli K, Krakoff IH, Khokhar AR:** Pharmacological studies with new liposome-entrapped cisplatin derivatives. In: *Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy*. Ed by Howell SB, Plenum Publishing Corporation, New York. pp 377-390, 1991.
6. **Perez-Soler R, Khokhar AR, Priebe W, Krakoff IH:** Development of new lipophilic anticancer agents entrapped in liposomes. In: *Drug Targeting and Delivery, Vol 2: Liposomes in drug delivery*. Ed by Gregoriadis G, Florence AT and Patel HM. Harwood Academic Publishers; Chur, Switzerland, pp 1-9, 1993.
7. **Priebe W, Perez-Soler R.** Design and tumor targeting of anthracyclines able to

- overcome multidrug resistance: a double-advantage approach. *Pharm. and Therapeutics* 60:215-234, 1993.
8. **Perez-Soler R**, Sugarman S, Zou Y, Priebe W. Use of drug carriers to ameliorate the antitumor properties of anthracycline antibiotics. In: Anthracycline antibiotics: new analogs, methods of delivery and mechanisms of action. Ed by Priebe W. ACS Symposium, Washington, DC, Series 574, pp 300-319, 1995
 9. Priebe W, Skibicki P, Varela O, Neamati N, Sznajdman M, Dziewiszek K, Gryniewicz G, Horton D, Zou Y, Ling YH, **Perez-Soler R**. Non-cross resistant anthracyclines with reduced basicity and increased stability of the glycosidic bond. In: Anthracycline antibiotics: new analogs, methods of delivery and mechanisms of action. Ed by Priebe W. ACS Symposium, Washington, DC, Series 574, pp 14-46, 1995.
 10. **Perez-Soler R**. The use of liposomes as delivery vehicles in biological systems. In: Liposome-mediated cancer chemotherapy. Ed by Sugarman S and Perez-Soler R. R.G. Landes Company, Austin, Texas , 1995.
 11. Priebe W, **Perez-Soler R**. Sugar-modified anthracyclines: a search for drugs able to overcome multidrug resistance. In: Carbohydrates: Targets for Rational Drug Design. Z.J. Witczak and K.A. Nieforth (Eds.) Marcel Dekker Inc., New York, 1996.
 12. Shin DM, **Perez-Soler R**, Hittelman WN, Hong WK. Epidermal growth factor receptor expression in head and neck tumorigenesis and saturation of EGFR with monoclonal antibody RG83852. In: EGF Receptor in tumor growth and progression. Ed by RB Lichtner, and RN Harkins. Springer-Verlag, Heidelberg, 1997.
 13. **Perez-Soler R**, Mendelsohn J. Growth factors receptors as a target for therapy. In: Lung Cancer. Ed by Roth JA, Cox JD, Hong WK., pp 309-341, Blackwell Science, Inc. Cambridge, MA, 1998.
 14. **Perez-Soler R**, Zou Y. Liposomes as carriers of hydrophobic antitumor agents. In: Medical Applications of Liposomes. Ed by Lasic DD, Papahadjopoulos D. Elsevier, pp.283-296, 1998.
 15. **Perez-Soler R**, Muggia FM. Investigational drugs. In: Haskell CM, Editor. Cancer Treatment, 5th Edition. Philadelphia: W.B. Saunders Company, 2001:475-482.

V. Abstracts, Published:

1. **Perez-Soler R**, Esteban R, Pedreira JD, Vargas V, Guardia J, Bacardi R: Afectacion hepatica en el mieloma multiple. Fourteenth Annual Meeting of the Spanish Society of Internal Medicine. Madrid, Spain, 1981.
2. **Perez-Soler R**, Esteban R, Pico M, Pedreira JD, Vargas V, Guardia J, Bacardi R: Estudio de la funcion plaquetar en el alcoholismo. Fourteenth Annual Meeting of the Spanish Society of Internal Medicine. Madrid, Spain, 1981.
3. Vargas V, Pedreira JD, **Perez-Soler R**, Esteban R, Hernandez JM, Guardia J, Bacardi R: Transmision placentaria de los anticuerpos antihepatitis B. Fourteenth Annual Meeting of the Spanish Society of Internal Medicine. Madrid, Spain, 1981.
4. Esteban R, Genesca J, **Perez-Soler R**, Cervantes M, Allende E, Guardia J: Hepatitis medicamentosa. Fifteenth Annual Meeting of the Spanish Society of Internal Medicine. Lanzarote, Spain, 1982.
5. Cervantes M, Montserrat E, Garcia Sureda D, Esteban R, Porta F, **Perez-Soler R**, Rius JM, Guardia J: Valor diagnostico de la gammagrafia hepatica y la ecografia abdominal en los pacientes con hepatomegalia. Fifteenth Annual Meeting of the Spanish Society of Internal Medicine. Lanzarote, Spain, 1982.
6. **Perez-Soler R**, Esteban R, Pico M, Cervantes M, Guardia J, Bacardi R: Efectos del alcohol en la funcion plaquetar: estudios *in vitro* y en individuos sanos tras ingesta de

- alcohol. Fifteenth Annual Meeting of the Spanish Society of Internal Medicine. Lanzarote, Spain, 1982.
7. **Perez-Soler R**, Pico M, Monasterio I: Ethanol induced platelet dysfunction. A study in heavy drinkers. *Proceed Seventh International Congress on Thrombosis (Hemostasis)* 88, 1982.
8. **Perez-Soler R**, Pico M, Monasterio I: Ethanol induced platelet dysfunction. An experimental study on abstemious individuals after moderate intake of alcohol. *Proceed Seventh International Congress on Thrombosis (Hemostasis)* 127, 1982.
9. **Perez-Soler R**, Pico M, Monasterio I: Ethanol induced platelet dysfunction. *In vitro* studies. *Proceed Seventh International Congress on Thrombosis (Hemostasis)* 195, 1982.
10. **Perez-Soler R**, Cabanillas F, McLaughlin P, Velasquez W, Hagemester FB, Riggs S, Fuller L: Clinical features and results of management of superior vena cava syndrome (SVCS) secondary to lymphoma. *Proceed AACR* 24:123, 1983.
11. **Perez-Soler R**, Lopez-Berestein G, Cabanillas F, Hagemester FB, McLaughlin P, Velasquez W, Drewinko B, Hersh EM: Impaired superoxide anion (O_2^-) release by peripheral blood monocytes (PBM) in Hodgkin's disease. *Blood* 62:195a, 1983.
12. **Perez-Soler R**, Lopez-Berestein G, Cabanillas F, Salvador P, Velasquez W, Riggs S, Hersh EM: Monocyte function measured by superoxide (O_2^-) production in Hodgkin disease and malignant lymphoma. *Proceed AACR* 25:267, 1984.
13. **Perez-Soler R**, Cabanillas F, Smith T, Freireich EJ, Krakoff IH: Prophylaxis of CNS relapse with combined systemic and intrathecal (IT) methotrexate (MTX) in diffuse lymphoma of aggressive histology. *Proceed ASCO* 3:250, 1984.
14. Richman SP, Lopez-Berestein G, Woodcock TM, Salley K, **Perez-Soler R**: Pharmacology of doxorubicin uptake into human monocytes *in vitro*. *Proceed AACR* 255:163, 1984.
15. Kasi LP, **Perez-Soler R**, Jahn M, Wright K, Lopez-Berestein G: *In vivo* distribution of radiolabeled multilamellar liposomes injected subcutaneously and intralymphatically in rats and dogs. *J Nucl Med* 26:330, 1985.
16. **Perez-Soler R**, Lopez-Berestein G, Kasi L, Cabanillas F, Jahns M, Glenn H, Haynie T, Hersh EM: Distribution of ^{99m}Tc -labeled multilamellar liposomes (MLV) in patients (pts) with Hodgkin disease (HD). *Proceed AACR* 26:161, 1985.
17. **Perez-Soler R**, Khokhar AR, Lopez-Berestein G: Treatment and prophylaxis of experimental liver metastases with cis-bis-neodecanoato-1,2-diamino-cyclohexane platinum (II) encapsulated in liposomes. *Proceed AACR* 27:403, 1986.
18. Lautersztain J, **Perez-Soler R**, Khokhar AR, Lu K, Newman RA, Lopez-Berestein G: Pharmacokinetics and tissue distribution of liposome encapsulated N-decyl-iminodiacetato-1,2-diaminocyclohexane platinum (II). *Proceed AACR* 27:405, 1986.
19. **Perez-Soler R**, Khokhar AR, Lopez-Berestein G: Toxicity and antitumor activity of lipophilic cis-platinum (CDDP) analogues encapsulated in multilamellar liposomes. *Proceed Fourteenth Int Cancer Congress*, Budapest, 1191, 1986.
20. Wright KC, Jahns MF, Kasi L, Hashimoto S, **Perez-Soler R**, Haynie T, Wallace S: Liposome distribution after arterial and venous and infusion. *Investigative Radiology* 22:528, 1987.
21. Schmidt KL, Lautersztain J, Khokhar AR, Mitchell PA, **Perez-Soler R**: Ultrastructural and freeze fracture localization of multilamellar liposomes containing a lipophilic cisplatin analogue in normal tissues and liver metastases of M5076 reticulosarcoma. *Gastroenterology* 92:1770, 1987.
22. Lautersztain J, **Perez-Soler R**, Lopez-Berestein G, Turpin J, Williams EP, Schmidt KL, Khokhar AR: Cellular pharmacology and ultrastructural localization of liposome entrapped

- cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-platinum (II) (L-NDDP). *Proceed AACR* 28:419, 1987.
23. Drewinko B, Yang LY, Khokhar AR, Lautersztain J, **Perez-Soler R**: Reversal of resistance to cisplatin by treatment with liposome-trapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP). *Proceed AACR* 28:315, 1987.
 24. **Perez-Soler R**, Khokhar AR, Wright K, Lautersztain J, Lopez-Berestein G: Toxicity in mice and dogs of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP). *Proceed AACR* 28:441, 1987.
 25. Khokhar AR, Krakoff IH, **Perez-Soler R**: Chemical and biological studies on lipophilic carboxylato trans-R, R-1,2-diaminocyclohexane-platinum (II) complexes encapsulated in liposomes. *Proceed Fifth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemother* 367, 1987.
 26. **Perez-Soler R**, Wright K, Krakoff IH, Khokhar AR: Organ distribution, tumor uptake, and toxicity of liposome encapsulated cis-bis-neodecanoato-trans-R, R-1,2-diaminocyclohexane platinum (II) (L-NDDP). *Proceed International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemother* 391, 1987.
 27. **Perez-Soler R**: Design and development of liposome-dependent antitumor agents. *J Cell Biochem Suppl* 12B:249, 1988.
 28. **Perez-Soler R**, Khokhar AR, Lautersztain J, Stephens LC, Lopez-Berestein G: Chronic toxicity and pharmacology in dogs of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP). *Proceed AACR* 29:512, 1988.
 29. Lautersztain J, Moreno Y, Khokhar AR, **Perez-Soler R**: Interaction of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP) with serum lipoproteins. *Proceed AACR* 29:509, 1988.
 30. **Perez-Soler R**, Khokhar AR: Organ distribution, toxicity, and antitumor activity of free and liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (NDDP). *Proceed AACR* 29:509, 1988.
 31. Khokhar AR, Al-Baker S, Krakoff IH, **Perez-Soler R**: Toxicity and antitumor studies of lipophilic cisplatin analogues entrapped in liposomes. *Proceed AACR* 29:344, 1988.
 32. **Perez-Soler R**: Development of liposome-dependent platinum compounds. *Cancer Invest* 6:33-34, 1988.
 33. **Perez-Soler R**, Khokhar AR, Lautersztain J, Ajani J, Dexeus F, Raber M, Lopez-Berestein G: Phase I clinical and pharmacology study of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II). *Proceed Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy* Abst. 204, Amsterdam, 1989.
 34. Priebe W, Neamati NM, **Perez-Soler R**: Analogues of esorubicin deaminated at C-3'. *197th Am Chem Soc Meet* 197:CARB-40, 1989.
 35. **Perez-Soler R**, Khokhar AR, Lautersztain J, Ajani J, Dexeus F, Raber M, Lopez-Berestein G: Phase I clinical and pharmacology study of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II). *Proceed ASCO* 8:67, 1989.
 36. Priebe W, Neamati NM **Perez-Soler R**: Novel anthracycline antibiotics deoxygenated at C-4'. *Proceed AACR* 30:575, 1989.
 37. Lautersztain J, Acton EM, **Perez-Soler R**, Lopez-Berestein G: Toxicity and antitumor activity of microparticle entrapped cyanomorpholino doxorubicin. *Proceed AACR* 30:604, 1989.
 38. Khokhar AR, Al-Baker S, Krakoff IH, **Perez-Soler R**: Pharmacological, toxicological, and chemical studies on 1,2-diaminocyclohexane platinum (II) complexes entrapped in multilamellar vesicles. *Proceed AACR* 30:627, 1989.
 39. **Perez-Soler R**, Khokhar AR, Lautersztain J, Ajani J, Dexeus F, Raber M, Lopez-

- Berestein G: Phase I clinical and pharmacology study of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II). *Proceed 16th International Congress of Chemotherapy* Jerusalem, Israel, June 1989, p 179.
40. Priebe W, Gryniewicz G, Perez-Soler R: Anthracyclines modified at C'-2. *198th Am Chem Soc Na Meet* 198: CARB-25, 1989.
41. Perez-Soler R, Francis K, Brown T, Khokhar AR: Liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (I-NDDP): effect of lipid composition on biological activity. *Proceed AACR* 31:428, 1990.
42. Perez-Soler R, Priebe W: Anthracycline antibiotics with a high liposome entrapment: structural features and biological activity. *Proceed AACR* 31:428, 1990.
43. Khokhar AR, Al-Baker S, Krakoff IH, Perez-Soler R: Chemical and biological studies of hydrophobic cisplatin analogues entrapped in liposomes. *Proceed AACR* 31:333, 1990.
44. Khokhar AR, Al-Baker S, Krakoff IH, Perez-Soler R: Chemical and biological studies of hydrophobic cisplatin analogues entrapped in liposomes. *Proceed 15th International Cancer Congress*, Hamburg, 1990, p 604.
45. Priebe W, Van NT, Perez-Soler R: Biological effects of deamination at C-3'. Evaluation of 3'-hydroxy-doxorubicin (Hydroxyrubicin). *J Cancer Res Clin Oncol* 116 (suppl., Part I): 439, 1990.
46. Perez-Soler R, Priebe W: Formulation and biological studies with liposome-entrapped 2'-iodo-3'-hydroxy-4'-epi-4-demethoxy doxorubicin (Annamycin). *J Cancer Res Clin Oncol* 116 (suppl., Part I): 603, 1990.
47. Siddik ZH, Perez-Soler R, Khokhar AR, Pazdur R, Roh MS, Francis K, Chase J, Krakoff IH: Clinical pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diamino- cyclohexane platinum (II) (L-NDDP) administered by hepatic arterial infusion. *Proceedings of the Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy*, San Diego, CA 1991.
48. Khokhar AR, Al-Baker S, Krakoff IH, Perez-Soler R: Synthesis, characterization and biological studies of lipophilic cisplatin analogues entrapped in liposomes. *Proceedings of the Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy*, San Diego, CA 1991.
49. Chase J, Wood J, Pazdur R, Khokhar AR, Perez-Soler R, Siddik ZH, Roh M. Phase I study of hepatic arterial infusion of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diamino-cyclohexane platinum (II) (L-NDDP). *Proceed AACR* 32:420, 1991.
50. Khokhar AR, Al-Baker S, Krakoff IH, Perez-Soler R. Development of liposome-encapsulated lipophilic cisplatin analogues. *Proceed AACR* 32:420, 1991.
51. Perez-Soler R, Siddik ZH, Al-Baker S, Francis K, Yang LY, Khokhar AR. Lipophilic cisplatin analogues entrapped in liposomes: role of chemical structure and liposome composition. *Proceed AACR* 32:408, 1991.
52. Perez-Soler R, Brown T, Priebe W. Preclinical studies with a lipophilic anthracycline derivative entrapped in liposomes. *Proceed AACR* 32:381, 1991.
53. Priebe W, Van T, Perez-Soler R. Activity of 3'-deaminated anthracyclines against MDR cells. *Proceed AACR* 32:378, 1991.
54. Siddik ZH, Perez-Soler R, Khokhar AR, Pazdur R, Roh MS, Francis K, Chase J, Krakoff IH. Clinical pharmacokinetics of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP). *Proceed AACR* 32:176, 1991.
55. Priebe W, Neamati NM, Gryniewicz G, Perez-Soler R. 2'-bromo anthracyclines. *Proceed Am Chem Soc Meet* 201: CARB-11, 1991.
56. Priebe W, Neamati NM, Perez-Soler R. 2'-3'-dihydroxy-4'-deoxy-daunorubicin and doxorubicin. *Proceed Am Chem Soc Meet* 201: CARB-36, 1991.
57. Vadieli K, Siddik ZH, Khokhar AR, Perez-Soler R. Pharmacokinetic and tissue

- distribution of liposomal cis-bis-neodecanoato-trans-R, R- 1, 2- diaminocyclohexane platinum (II) (L-NDDP) following single IV and IP dose in the rat. *Pharm Res* 8 (Suppl) S-290, 1991.
58. Priebe W, Neamati N, Gryniewicz G, **Perez-Soler R**: Synthesis of 3'- thio sugars and related 3'- mercapto - anthracyclines. *Am Chem Soc Meet* 202: CARB-32, 1991.
 59. **Perez-Soler R**, Donato NJ, Zhang HZ, Shin DM, Brewer HM, Rosenblum MG, Tornos C, Hong WK, Murray JL: Phase I Study of anti EGFR monoclonal antibody RG 83852 in patients with non-small cell lung cancer. *Antibody Immunoconjugates and Radiopharmaceuticals* 5:148, 1992.
 60. **Perez Soler R**, Ling YH, Priebe W: Overcoming of multidrug resistance and enhanced blood-brain barrier permeability with the use of lipophilic anthracyclines. *Proceed 7th NCI-EORTC Symposium in New Drugs in Cancer Therapy* p 75, Amsterdam, 1992.
 61. Khokhar AR, Al-Baker S, Krakoff IH, **Perez-Soler R**: Synthesis, toxicity, and efficacy studies of highly lipophilic cisplatin analogues entrapped in liposomes. *Proceed 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy* p 127, Amsterdam, 1992.
 62. **Perez-Soler R**, Donato NJ, Zhang HZ, Shin DM, Brewer HM, Rosenblum MG, Tornos C, Hong WK, Murray JL: Phase I study of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) RG83852 in patients with non-small cell lung cancer. *Proceed ASCO* 11:255,1992.
 63. Fossella FV, Lee JS, Mortensen T, Shin DM, **Perez-Soler R**, Heyne K, Carr DT, Hong WK: Phase II study of cisplatin (P) + prolonged oral VP-16 (E) for non-small cell lung cancer (NSCLC). *Proceed ASCO* 11:305, 1992.
 64. Zou Y, Ling YH, Priebe W, **Perez-Soler R**: Pharmacokinetics and organ distribution of 2'-I-3'-OH-4'-epi-4-demethoxydoxorubicin (Annamycin) entrapped in multilamellar vesicles. *Proceed AACR* 33:447, 1992.
 65. Ling YH, Yang LY, Priebe W, **Perez-Soler R**: Characterization of DNA lesions induced by 2'-I-3'-OH-4'-epi-4-demethoxy-doxorubicin (A), a non-cross resistant doxorubicin (D) analogue with high affinity for lipid membranes. *Proceed AACR* 33:487, 1992.
 66. Khokhar AR, Al-Baker S, Krakoff IH, **Perez-Soler R**: Chemical and biological studies of highly lipophilic cisplatin analogues entrapped in liposomes. *Proceed AACR* 33:540, 1992.
 67. **Perez-Soler R**, Nguyen T, Yang LY, Siddik ZH, Khokhar AR: Cellular uptake studies with a lipophilic cisplatin (CDDP) analogue entrapped in multilamellar liposomes in LoVo and LoVo/CDDP cells. *Proceed AACR* 33:446, 1992.
 68. Priebe W, Neamati N, Gryniewicz G, Van NT, Burke TG, **Perez-Soler R**: 2'-bromo anthracyclines: Synthesis and non-cross resistant properties. *Proceed AACR* 33:557, 1992.
 69. Priebe W, Van WT, **Perez-Soler R**: Reduction of basicity of anthracyclines as a method to overcome multidrug resistance. *Am Chem Soc Meet* 203: MEDI-40, 1992.
 70. Priebe W, Neamati N, Varela O, Horton D, Skibicki P, **Perez-Soler R**, Van NT, Gryniewicz G, and Dziewiszek K. Novel non-cross resistant anthracycline antibiotics with modified basicity. *Am Chem Soc Meet* 205:CARB 13, 1993.
 71. Dziewiszek K, Gryniewicz G, **Perez-Soler R**, Priebe W. Synthesis of anthracyclines fluorinated at 6'-position. *Am Chem Soc Meet* 205:CARB 29, 1993.
 72. Skibicki P, **Perez-Soler R**, Burke TG, Priebe W. Synthesis and biological evaluation of non-cross-resistant 3'-O-benzyl anthracyclines. *Am Chem Soc Meet* 205:CARB 30, 1993.
 73. **Perez-Soler R**. Use of drug carriers to ameliorate the anticancer properties of anthracycline antibiotics. *Am Chem Soc Meet* 205:CARB 61, 1993.
 74. **Perez-Soler R**, Siddik ZH, Chase J, Al-Baker S, Khokhar AR, Pazdur R. Phase I clinical

- and pharmacology study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II)(L-NDDP) administered into the hepatic artery (IHA). *Proceed ASCO* 12:410 p 153, 1993.
75. Shin DM, **Perez-Soler R**, Donato NJ, Shah T, Tornos C, Hittelman WN, Hong WK, Murray JL. Tumor epidermal growth factor receptor (EGFR) saturation and proliferating cell nuclear antigen (PCNA) expression in patients treated with anti-EGFR monoclonal antibody (MoAb) RG83852 [In phase I clinical study]. *Proceed ASCO* 12:940 p 289, 1993.
 76. Fossella FV, Lippman SM, Pang A, Greenberg J, Shin D, Murphy W, **Perez-Soler R**, Raber M, and Hong WK. Phase I/II study of gemcitabine (G) by 30 minute weekly intravenous (iv) infusion x 3 wks every 4 weeks for non-small cell lung cancer (NSCLC). *Proceed ASCO* 12:1082 p 326, 1993.
 77. Ling YH, Priebe W, Tseng MT and **Perez-Soler R**. DNA fragmentation and apoptosis induced by doxorubicin (Dox) and its non cross-resistant analog annamycin (Ann) in P388 parent and multidrug resistant (MDR) cells. *Proceed AACR* 34:1734 p 291, 1993.
 78. **Perez-Soler R**, Ling YH, Zou Y, Priebe W. Cellular pharmacology of free and liposome-entrapped Annamycin (Ann) in KB/S and KB/R cells. *Proceed AACR* 34:1929 p 324, 1993.
 79. Ling YH, Zou Y, Priebe W, **Perez-Soler R**. *In vitro* cytotoxicity and reversal of multidrug resistance by monensin in KB sensitive and resistant cell lines. *Proceed AACR* 34:1930 p 324, 1993.
 80. Solary E, Ling YL, **Perez-Soler R**, Priebe W, and Pommier Y. Hydroxyrubicin, a deaminated derivative of doxorubicin is a topoisomerase II inhibitor which partially overcomes multidrug resistance. *Proceed AACR* 34:1959 p 329, 1993.
 81. Burke TG, Mehta R, **Perez-Soler R**, and Priebe W. Altered membrane and DNA interactions of 3'-O-benzyl anthracyclines. *Proceed AACR* 34:1971 p 331, 1993.
 82. Donato NJ, Zou Y, and **Perez-Soler R**. Upregulation of EGF receptor tyrosine kinase activity *in vivo* by monoclonal antibody (A108) specific for EGF receptor. *Proceed AACR* 34:2045 p 343, 1993. **Perez-Soler R**, Han I, Al-Baker S, Khokhar AR. Lipophilic platinum compounds entrapped in liposomes; enhanced intraliposomal stability and preserved antitumor activity by using analogs with linear aliphatic leaving groups. *Proceed AACR* 34:2182 p 366, 1993.
 83. Zou Y, Reddy S, Ling YH, Priebe W, **Perez-Soler R**. *In vivo* antitumor activity of the lipophilic anthracycline annamycin (Ann) entrapped in liposomes against KB/MDR human s.c. xenografts, lung Lewis lung carcinoma (LLC), and s.c. M5076 reticulosarcoma. *Proceed AACR* 34:2183 p 366, 1993.
 84. Priebe W, Skibicki P, Burke TG, and **Perez-Soler R**. Novel 3'-O-benzyl anthracyclines. Synthesis and non-cross resistance properties. *Proceed AACR* 34:2259 p 379, 1993.
 85. Han I, Khokhar AR, Ling YH, Al-Baker S, and **Perez-Soler R**. Cellular pharmacology of liposome-entrapped cis-bis-neodecanoato trans-R,R-1,2-diaminocyclohexane platinum (L-NDDP) in A2780 and A2780/PDD human ovarian carcinoma cells. *Proceed AACR* 34:2414 p 405, 1993.
 86. Al-Baker S, **Perez-Soler R**, Han I, and Khokhar AR. Synthesis and antitumor activity of bis(carboxylato)(1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes. *Proceed AACR* 34:2415 p 405, 1993.
 87. Sugarman S and **Perez-Soler R**. Liposomal camptothecin: formulation and cytotoxicity against KB cells. *Proceed AACR* 34:2519 p 422, 1993.
 88. **Perez-Soler R**, Glisson BS, Kane J, Raber MN, Hong WK. Phase II study of Topotecan in patients with non-small cell lung cancer. *European J Cancer* 29A, Suppl

- 6:S162,1993.
89. Consoli U, Priebe W, Ling YH, Mahadivya R, **Perez-Soler R**. Annamycin, a novel anthracycline, is not affected by P-glycoprotein-related MDR: comparison with doxorubicin and idarubicin. *Blood* 82:(Suppl 1):2579, 1993.
90. Ling YH, Zou Y, **Perez-Soler R**. Subcellular distribution of annamycin (Ann), a lipophilic and non cross-resistant analogue of doxorubicin (Dox) in KB-3-1 and KB-V-1 (MDR) cells. *Proceed AACR* 35:2311 p 388, 1994
91. **Perez-Soler R**, Ling YH, El-Naggar AK, and Priebe W. Effects of anthracycline antibiotics on cell cycle progression and P34^{cdc2} kinase activity in P388 cells. *Proceed AACR* 35:2312 p 388, 1994.
92. Han I, Al-Baker S, Khokhar AR, and **Perez-Soler R**. Liposomal-platinum (II) compounds (L-Pt): optimization of formulation parameters. *Proceed AACR* 35:2482 p 416, 1994.
93. Neamati N, **Perez-Soler R**, Andreeff M, and Priebe W. Cytotoxicity and cellular pharmacology of 2'-Bromo-4'-epi-daunorubicin (WP 401), a novel non cross-resistant anthracycline analog. *Proceed AACR* 35:2525 p 423, 1994.
94. Zou Y, Wasan KM, Reddy S, Ling YH, Priebe W, and **Perez-Soler R**. Pharmacokinetics and tissue distribution of different liposomal formulations of Annamycin in tumor-bearing mice. *Proceed AACR* 35:2534 p 425, 1994.
95. Mori A, Wu S-P, **Perez-Soler R**, Khokhar AR, Chang M-J, Johnson CS, and Huang L. Characterization of long-circulating liposomes containing a lipophilic platinum complex and their potential applications in tumor therapy. *Proceed AACR* 35:2587 p 434, 1994.
61. Fossella FV, Raber M, Lee JS, Murphy WK, Lippman S, Calayag M, Pang A, Shin DM, Glisson B, Benner S, Huber M, **Perez-Soler R**, Hong WK. Taxotere™ (Docetaxel), an active agent for recurrent/metastatic non-small cell lung cancer (NSCLC): Preliminary report of a phase II study. *Proceed ASCO* 13:1114 p 336, 1994.
97. Fossella FV, Lee JS, Shin DM, Calayag M, **Perez-Soler R**, Huber M, Murphy WK, Benner S, Lippman S, Glisson B, Raber M, Hong WK. Taxotere™ (Docetaxel:DTXL), an active agent for platinum-refractory non-small cell lung cancer (NSCLC): preliminary report of a phase II study. *Proceed ASCO* 13:1115 p 336, 1994.
98. **Perez-Soler R**, Glisson BS, Kane J, Lee J, Raber MN, Hong WK. Phase II study of Topotecan in patients with non-small cell lung cancer (NSCLC) previously untreated. *Proceed ASCO* 13:1223 p 363, 1994.
99. Fossella FV, Lee JS, Murphy WK, Lippman S, Calayag M, Shin DM, Glisson B, Benner S, Huber M, **Perez-Soler R**, Raber M, Hong WK. Taxotere (Docetaxel: DTXL), an active agent for non-small cell lung cancer (NSCLC): preliminary report of 2 phase II studies. *Lung Cancer* 11 (Suppl 1):118, 1994
100. **Perez-Soler R**, Glisson BS, Kane J, Lee JS, Lee J, Raber MN, Hong WK. Phase II studies of topotecan in patients with non-small cell lung cancer (NSCLC) previously untreated and patients with small cell lung (SCLC) cancer refractory to etoposide. *Lung Cancer* 11 (Suppl 1):126, 1994.
101. Priebe W, Przewloka T, Foky I, **Perez-Soler R**, Safa AR. Hydroxyrubicin: A 3'-hydroxy anthracycline antibiotic, does not inhibit daunorubicin photoaffinity labeling of P-gp. *Proceed AACR* 36:1989 p.334, 1995.
102. Zou Y, Reddy S, Wu QP, Priebe W, **Perez-Soler R**. Preparation and Pharmacokinetics of Annamycin Entrapped in Liposomes. *Proceed AACR* 36:2145 p.360, 1995.
103. **Perez-Soler R**, Zou Y, Stephens C, Reddy S, Priebe W. Preclinical toxicity of the lipophilic & non-cross resistant anthracycline Annamycin incorporated in liposomes. *Proceed AACR* 36:2183 p.366, 1995.
104. Ling YH, Neamati N, **Perez-Soler R**. M-Phase arrest, stimulation of p34^{cdc2} kinase

- activity, and enhancement of cdc2/cyclin B accumulation by Vinblastine, Nocodazole, and Taxol. *Proceed AACR* 36:2708 p.454, 1995.
105. Fossella FV, Lippman SM, Tarassoff P, Shin DM, Calayag M, Lee JS, Murphy WK, **Perez-Soler R**, Glisson BS, Hong WK. Phase I/II Study of Gemcitabine, an active agent for advanced non-small cell lung cancer (NSCLC). *Proceed ASCO* 14:1144 p.371, 1995.
 106. Murphy WK, Huber M, Fosella FV, Lee JS, Glisson BS, **Perez-Soler R**, Shin DM, Kurie JM, Lippman SM, Wester M, Hong WK. Phase I Study of Taxol (t), Cisplatin (P), and Etoposide (E) with GCSF (G) in patients with NSCLC. *Proceed ASCO* 14:1076 p.354, 1995.
 107. Fossella FV, Newman RA, Gorelick KJ, Wester M, Madden T, Kunz AY, Murphy WK, Shin DM, Huber M, Lee JS, **Perez-Soler R**. Phase I trial of GL331, a novel Topoisomerase II (T-II) Inhibitor, for advanced refractory cancer. *Proceed ASCO* 14:1571 p.482, 1995.
 108. Zou Y, Priebe W, **Perez-Soler R**. Preclinical Studies with Annamycin, a new lipophilic anthracycline antibiotic with *in vivo* antitumor activity against tumors expressing the MDR1 Phenotype. *Proceed ASCO* 14:1597 p.489, 1995.
 109. **Perez-Soler R**, Glisson BS, Lee JS, Fossella FV, Lippman SM, Huber MH, Shin DM, Murphy WK, Hong WK. Phase II Study of Topotecan in patients with small cell lung cancer (SCLC) refractory to etoposide. *Proceed ASCO* 14:1076 p.354, 1995.
 110. Krawczyk L, Lothstein T, Sweatman R, **Perez-Soler R**, and Priebe W. Synthesis and cytotoxic properties of 14-o-acylated hydroxyrubicins. *211th American Chemical Society National Meeting*, CARB 48, 1996.
 111. Priebe W, Przewloka T, Fokt R, **Perez-Soler R**, and Safa AR. Photoaffinity labeling of P-glycoprotein and its inhibition by charged and uncharged anthracyclines. *211th American Chemistry Society National Meeting*, CARB 49, 1996.
 112. **Perez-Soler R**, Shin DM, Siddik ZH, Murphy WK, Huber M, Lee JS, Khokhar AR, Hong WK. Phase I clinical and pharmacological study of liposome-entrapped NDDP (L-NDDP) administered intrapleurally in patients with malignant pleural effusions. *9th NCI-EORTC Symposium, Abstract Book*, 357, p.102, 1996.
 113. Donato NJ, Ling YH, Siddik Z, and **Perez-Soler R**. Receptor tyrosine kinase expression as a modulator of cis-platinum resistance and sensitivity. *Proceed AACR* 37:223 p.32, 1996.
 114. Poirot K, Zou Y, and **Perez-Soler R**. Liposomal-camptothecin composed of cationic phospholipids containing unsaturated fatty acids: Formulation and cytotoxicity studies. *Proceed AACR* 37:2039 p.300, 1996.
 115. Ling YH, Neamati N, Schneider E, Austin Doyle L, Priebe W, and **Perez-Soler R**. Annamycin circumvents MRP in breast and small cell lung cancer cell lines. *Proceed AACR* 37:2245 p.329, 1996.
 117. Zou Y, Hao M, Wu QP, Lozano G, and **Perez-Soler R**. Treatment of endobronchial implants of human non-small cell lung cancer with lipid-p53 gene complexes. *Proceed AACR* 37:2318 p.340, 1996.
 118. Ling YH, Consoli U, and **Perez-Soler R**. Activation of cyclin B1 dependent kinase activity and induction of programmed cell death (PCD) in KB cells treated with Taxol (T). *Proceed AACR* 37:2436 p.357, 1996.
 119. Han I, Khokhar AR, and **Perez-Soler R**. Intraliposomal conversion of lipophilic 1,2-DACH-bisalkyl-platinum(II) complexes into DACH-Pt-CI2 (II). *Proceed AACR* 37:2740 p.401, 1996.
 120. Lee JS, Shin DM, Kurie JM, Heyne K, Wester M, Murphy WK, **Perez-Soler R**, Glisson BS, Fossella FV, and Hong WK. Acceleration of cisplatin/etoposide (PE) chemotherapy

- by filgrastim in patients with non-small cell lung cancer (NSCLC). *Proceed ASCO* 15:1175 p.390, 1996.
121. Fossella FV, Madden T, Wester M, Gorelick K, Murphy WK, Shin DM, **Perez-Soler R**, Lee JS, Rivera E, Kunz AY, and Newman R. Phase I trial of GL331, a novel topoisomerase-II inhibitors, for advanced refractory cancer. *Proceed ASCO* 15:1571 p.492, 1996.
 122. **Perez-Soler R**, Shin DM, Siddik ZH, Murphy WK, Huber M, Lee, JS, Khokhar AR, and Hong WK. Phase I clinical and pharmacological study of liposome-entrapped NDDP (L-NDDP) administered intrapleurally (IPL) in patients with malignant pleural effusions. *Proceed ASCO* 15:1572 p.492, 1996.
 123. Zou Y, Ling YH, Lozano G, **Perez-Soler R**. Efficacy of p53 gene delivered by non-viral carrier against human lung cancer cells. *Proceed AACR* 38:64 p.10, 1997.
 124. Ling YH, Yang Y, **Perez-Soler**. Expression and activation of mos gene product is associated with Taxol-induced apoptosis in human ovarian cancer SKOV3 cells. *Proceed AACR* 38:1906 p284, 1997.
 125. Lee JS, **Perez-Soler R**, Kemp BL, Lotan R, Hong WK. Loss of blood group antigen A expression in human non-small cell lung cancer xenografts. *Proceeds AACR* 38:2195 p327, 1997.
 126. Priebe W, Chaires JB, Fokt I, Przewloka T, Leng T, Ling YH, **Perez-Soler R**. Targeting DNA with anthracyclines and bisanthracyclines. *Proceed AACR* 38:2631 p. 392, 1997.
 127. Priebe W, Fokt I, Przewloka T, Ling YH, **Perez-Soler R**. Novel orally active anthracyclines. *Proceed AACR* 38:4107 p.611, 1997.
 128. Booser D, Esparza-Guerra L, Zou Y, Priebe W, **Perez-Soler R**: Liposomal annamycin. Phase I clinical and pharmacological study. *Proceed ASCO* 16:762 p217a, 1997.
 129. Ling YH, Kemp B, Wu QP, **Perez-Soler R**: Determinants and correlates of sensitivity to Taxol in non-small cell lung cancer heterotransplants. *Proceed ASCO* 16:852 p241a, 1997.
 130. **Perez-Soler R**, Khuri F, Pisters KM, Robinson R, Wimberly A, Lee JK, Fossella FV: Phase II study of topotecan in patients with squamous carcinoma of the lung previously untreated with chemotherapy. *Proceed ASCO* 16:1619 p450a, 1997.
 131. Glisson BS, Kurie JM, Fox NJ, Murphy WK, Winn RJ, **Perez-Soler R**, Pisters KMW, Shin DM, Hong WK. Phase I-II study of cisplatin, etoposide, and paclitaxel (PET) in patients with extensive small cell lung cancer (ESCLC). *Proceed ASCO* 16:1635 p455a, 1997.
 132. MacLean DS, **Perez-Soler R**: The analysis of liposomal cis-bis neodecanoato-trans-R,R-1,2-diamminocyclohexane platinum (II) (L-NDDP) degradation by HPLC, AAS, and radiosotopic methods. *Proceed Annual AAPS Meeting* (Abstract #2213), Boston, MA, 1997.
 133. Kumi R, Zou YY, Chow D, and **Perez-Soler R**: Chemical stability and preliminary antitumor activity of a high phase transition liposomal annamycin delivery system. *Proceed Annual AAPS Meeting* (Abstract #2201), Boston, MA, 1997.
 134. Yang YS, Mao L, Kalapurakal SK, Kemp BL, **Perez-Soler R**, Hong WK, Lee JS: The effect of p53 expression and mutation of primary non-small cell lung cancer on the heterotransplant tumor growth in nude mice. *Proceed AACR* 39:192, p28, 1998.
 135. Ling YH, Tornos C, **Perez-Soler R**: Role of bcl-2 phosphorylation in mitotic arrest and apoptosis in HeLa cells treated with antitubulin agents. *Proceed AACR* 39:612, p90, 1998.
 136. Priebe W, Ling YH, Fokt I, Przewloka T, Chaires JB, **Perez-Soler R**: Unique biological activity of anthracycline-based bisintercalators. *Proceed AACR* 39:2074,

- p304, 1998.
137. **Perez-Soler R**, Ling YH, Zou Y: Sensitization to CDDP by cationic liposome-mediated transfection of wt p53 in p53 null H358 cells. *Proceed AACR* 39:3485, p512, 1998.
 138. Zou Y, Zong G, Ling YH, Wu QP, Lozano G, **Perez-Soler R**: Treatment of endobronchial p53 mutant human lung cancer in nude mice with cationic lipid/p53 gene complexes. *Proceed AACR* 39:3525, p518, 1998.
 139. Lee JS, Kalapurakal SK, **Perez-Soler R**, Yamamoto F, Hong WK, Hittelman WN: Suppression of tumorigenic and metastatic potential of human lung cancer cells by histoblood group A transferase cDNAs. *Proceed AACR* 39:4423, p649, 1998.
 140. Kemp B, Ling Y-H, Wu QP, Mao L, Yang Y-S, Lee JS, **Perez-Soler R**: Determinants of sensitivity to taxol (T) in human non-small cell lung cancer (NSCLC) heterotransplants (HT). *Proceed ASCO* 17(743):193a, 1998.
 141. **Perez-Soler R**, Shin DM, Donato N, Radinsky R, Khuri F, Glisson BS, Shin H, Matsumoto T, Lawhorn K, Waksal H, Hong WK, Mendelsohn J: Tumor studies in patients with Head & Neck cancer treated with humanized anti-epidermal growth factor (EGFR) monoclonal antibody C225 in combination with cisplatin. *Proceed ASCO* 17(1514):393a, 1998.
 142. Swisher SG, Roth JA, Neumanitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Nesbitt JC, Nguyen D, Pisters KMW, Putnam Jr. JB, Shrumph DS, Shin DM, **Perez-Soler R**, Walsh GL: Adenoviral mediated p53 gene transfer in patients with advanced non-small cell lung cancer (NSCLC). *Proceed ASCO* 17(1659):431a, 1998.
 143. Lee JS, Komaki R, Touroutoglou N, Delclos M, Fox N, Glisson BS, **Perez-Soler R**, Fossella FV, Khuri FR, Hong WK: Erythropoietin (EPO) prevents anemia during concurrent chemoradiation therapy (rt) for locally-advanced inoperable non-small cell lung cancer (NSCLC). *Proceed ASCO* 17(1780):463a, 1998.
 144. Jiang, JD, Davis AS, Middleton K, Ling Y-H, **Perez-Soler R**, Holland JF, Bekesi JG. Molecular targets of 3-(Iodoacetamido)-benzoylurea: A new cancericidal tubulin ligand. *Proceed AACR* 40(8):2, 1999.
 145. Burke TG, Chavan AJ, Strode JT, Giovanella B, Yang D, Curran DP, Bom D, Josien H, Pommier Y, Zimmer S, Fraley KA, **Perez-Soler R**: Development and evaluation of a liposomal formulation of highly lipophilic 7-t-butydimethylsilyl-10-hydroxycamptothecin. *Proceed AACR* 40(752):113, 1999.
 146. Ling YH, Zou Y, **Perez-Soler R**: Wild-type p53 gene transfection induces senescence-like phenotype and loss of paclitaxel sensitivity in p53-null human non-small cell lung cancer (NSCLC) H358 cells. *Proceed AACR* 40(1901):286, 1999.
 147. **Perez-Soler R**, Ling YH, Mao L, Wu QP, Zeleniuch-Jacquotte A and Kemp B: In vivo sensitivity to paclitaxel (P) in human non-small cell lung cancer (NSCLC) heterotransplants (HT's): Role of Her-2, bax and bcl-2. *Proceed AACR* 40(1241):290, 1999.
 148. Yang L-Y, Li L, McLean D, Jiang H, Khokhar AR, **Perez-Soler R**: Inefficient repair of DNA adducts induced by cis-bis-neodecanoato-trans-R-R-1,2-diaminocyclohexane platinum (II) (NDDP) in a cell-free system. *Proceed AACR* 40(1952):294, 1999.
 149. Priebe W, Przewloka T, Fokt I, Ling Y-H, **Perez-Soler R**: Highly potent anthracycline-based antitumor agents. *Proceed AACR* 40(2001):301, 1999.
 150. Zou Y, Ling YH, **Perez-Soler R**: Treatment of orthotopic early lung cancer with regional administration of cisplatin combined with liposome-p53. *Proceed AACR* 40(3204):485, 1999.
 151. Lee JS, Komaki R, Touroutoglou N, Delclos M, Fox N, Glisson BS, **Perez-Soler R**,

- Fossella FV, Khuri FR, Hong WK: Erythropoietin plus iron supplement prevents significant anemia during concurrent chemo-radiation therapy in patients with locally-advanced inoperable non-small cell lung cancer. *Proceed AACR* 40(4233):642, 1999.
152. Verschraegen CF, Mansfield PF, Feig BW, Steger M, Wu QP, MacLean D, Siddik Z, **Perez-Soler R**, Hu W, Kudelka AP, Kavanagh JJ, Khokhar AR: Phase I study of an intraperitoneal liposomal cisplatin analog L-NDDP for treatment of peritoneal carcinomatosis. *Proceed ASCO* 18(1405):364a, 1999.
153. Mendelsohn J, Shin DM, Donato N, Khuri F, Radinsky R, Glisson BS, Shin HJ, Metz E, Pfister D, **Perez-Soler R**, Lawhorn K, Matsumoto T, Gunnett K, Falcey J, Waksal H, Hong WK: A phase I study of chimerized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC). *Proceed ASCO* 18(1502):388a, 1999.
154. **Perez-Soler R**, Walsh GL, Swisher SG, Shin HJC, Kemp BL, Terry K, Khuri FR, Fossella FV, Hong WK, Lopez-Berestein G, Khokhar AR, Shin DM: Phase II clinical study of a liposome entrapped cisplatin analog (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma. *Proceed ASCO* 18(1626):421a, 1999.
155. Herbst RS, Khuri FR, Jung M, Fossella FV, Lee JS, Glisson B, Shin DM, Pisters K, Papadimitrakopoulou V, Kurie J, **Perez-Soler R**, Liu D, Munden R, Hong WK: Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. *Proceed ASCO* 18(1782):462a, 1999.
156. Ling YH, Zhong Y, **Perez-Soler R**. Cleavage of β -catenin, γ -catenin, and APC protein mediated by caspases-3 and -7 during paclitaxel-induced apoptosis in human NSCLC H460 cells. *Proceed AACR* 41(904):142, 2000.
157. Burke TG, Houghton PJ, Bom D, Wu D, Kruszewski S, Pommier Y, Kohlhagen G, **Perez-Soler R**, Zimmer SG, Latus LJ, Charvan AJ, Curran DP. The novel silatecan DB-67 displays high lipophilicity, improved human blood stability, and potent anticancer activity *in vitro* and *in vivo*. *Proceed AACR* 41(1341):210, 2000.
158. Chodkiewicz C, Gomez JE, Ling YH, **Perez-Soler R**. COX-2 expression and *in vitro* and *in vivo* sensitivity to paclitaxel in non-small cell lung cancer. *Proceed AACR* 41(5508):867, 2000.
159. **Perez-Soler R**, Ling Y, Mendoza S, Ng B, Adams J, Elliott P, Muggia F, Liebes L. Effect of the proteasome inhibitor PS341 on cell cycle progression and cell cycle-related events: Implications for combination therapy with cell cycle-dependent agents. *Proceed ASCO* 19(740):190a, 2000.
160. Houghton PJ, Bom D, Wu D, Kruszewski S, Pommier Y, **Perez-Soler R**, Zimmer SG, Strode JT, Chavran AJ, Latus LJ, Curran DP. Anticancer activity of the novel DB-67 silatecan, a highly lipophilic liposomal camptothecin agent displaying improved intrinsic human blood and plasma stability and potent topoisomerase I activity. *Proceed ASCO* 19(766):197a, 2000.
161. Kim KB, Khuri FR, Shin DM, Papadimitrakopoulou V, Terry K, **Perez-Soler R**, Hong WK. Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. *Proceed ASCO* 19(858): 220a, 2000.
162. Lee JS, Pisters KM, Komaki R, Terry K, Glisson BS, **Perez-Soler R**, Fossella FV, Shin DM, Herbst RS, Khuri FR, Kurie JM, Hong WK. Paclitaxel and carboplatin chemotherapy as a primary treatment of brain metastases in patients with non-small cell lung cancer. *Proceed ASCO* 19(1962): 501a, 2000.
163. Gomez JE, Jagirdar J, Yee H, Zhong Y, Chodkiewicz C, **Perez-Soler R**. Progressive downregulation of E-cadherin during lung carcinogenesis. *Proceed ASCO* 19(2593):

- 657a, 2000.
164. Lee M, Campbell W, Huang YQ, **Perez-Soler R**, Karparkin S. Hirudin inhibits human tumor implantation and metastases in nude mice. *Blood* 96:818A, 2000.
 165. Zou Y, Hung MC, and **Perez-Soler R**: A Nonviral Gene Delivery System for the Treatment of Bronchial Premalignancy and Early Lung Cancer by Inhalation. *Proceed AACR* 42(145): 27, 2001.
 166. Zhong Y, Lopez-Barcons LA, and **Perez-Soler R**: Exogenous Expression of H-Cadherin Regulates Cell Adhesion, Contact Inhibition, and Cell Growth. *Proceed AACR* 42(1607): 299, 2001.
 167. Lee M, Campbell W, Huang YQ, **Perez-Soler R**, and Karparkin S: Hirudin Inhibits Human Tumor Implantation and Metastasis in Nude Mice. *Proceed AACR* 42(4256): 793, 2001.
 168. Haigentz M, Zhong Y, Cavaleri S, Yee H, and **Perez-Soler R**: Determinants of Successful Transplantation of Human Non-Small Cell Lung Cancer (NSCLC) Tumors in Nude Mice. *Proceed AACR* 42(4900): 913, 2001.
 169. **Perez-Soler R**, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ, Allen LF, Nadler PI, Bonomi P. A Phase II Trial of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor OSI-774, Following Platinum-Based Chemotherapy, in Patients (pts) with Advanced, EGFR-Expressing, Non-Small Cell Lung Cancer (NSCLC). *Proceed ASCO* 20(1235): 310a, 2001.
 170. Haigentz M, Gomez J, Xiong Q, Campbell W, Lee JS, **Perez-Soler R**. Clinical Relevance of Non-Small Cell Lung Cancer (NSCLC) Heterotransplants (HT) in Nude Mice. *Proceed ASCO* 20(1374): 344a, 2001.